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ABSTRACT 
 BACKGROUND: 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of young 
women. There is a spectacular increase in the prevalence of PCOS all over world 
especially in Asia. The condition seems to be on rise in Kashmir valley although 
systemic studies on the subject are underway. First line of treatment is often the oral 
contraceptive pills (OCP’s) as most of these women attend to various gynaecologists   
and they desire menstrual regulation. Since there is plethora of data that PCOS 
women have evidence of enhanced markers of inflammation and indicators of 
coagulation. Therefore treatment with OCP’s may worsen the metabolic, 
inflammatory and coagulation parameters in this population. We undertook this 
study to investigate the effect of OCP treatment procoagulant and proinflammatory 
markers in women with PCOS. The results may therefore translate in to the clinical 
practice. 
AIMS AND OBJECTIVES: 
Estimate and compare the impact of OCP’s on the proinflammatory and 
procoagulant activities in women with PCOS.  
SUBJECTS:  
The study was done as joint collaborative effort between departments of 
Endocrinology, Sher-i-Kashmir Institute of Medical Sciences, Soura and department 
of Clinical Biochemistry, University of Kashmir. We studied 51 women with a 
confirmed diagnosis of PCOS  who were drug naive (controls) and compare them 
with 30 PCOS women who received  Estrogen and progesterone (OCP’s) as  
treatment modality for approximate period of six months (cases). We investigated 
and compared clinical, anthropometric, hemodynamic, hormonal, metabolic, 
procoagulant and proinflammatory parameters of cases and controls. Rotterdom 
2003 Criteria was applied for making a positive diagnosis of PCOS after ruling out 
disorders such as hypothyroidism, hyperprolactinemia, Non classical congenital 
adrenal hyperplasia(NCAH), Cushing’s syndrome, androgen excreting adrenal or 
 ovarian lesion and androgen intake,. An informed consent was obtained from all the 
participants and the study was approved by the Institutional Ethics Committee. 
METHODS: 
The clinical assessment included detailed menstrual history, quantitation of 
hyperandrogenism (hirsutism, acne vulgaris, and male pattern hair growth), 
anthropometric assessment (height, weight, waist and hip circumference). 
Biochemical assessment involved two hour OGTT (oral glucose tolerance test) for 
glucose and insulin in additions to lipids. Plasma levels of s-ICAM (Soluble 
intercellular adhesion molecule), MCP-1(Monocyte chemoattractant protein 1), 
TNF-α (Tumor necrosis factor-α), PAI-1(Plasminogen activator inhabitor-1) and 
factor VIII were done to estimate severity of inflammation and procoagulant 
activities. Hormonal evaluation included  T4, thyroid stimulating hormone (TSH), 
cortisol (morning), luteinizing hormone (LH), follicle stimulating hormone (FSH), 
prolactin (PRL), 17-hydroxyprogesterone (17-OHP), and total testosterone (T). The 
samples for LH, FSH, T, and 17-OHP were collected on days 3–7 (early follicular 
phase) of spontaneous cycle or medroxyprogesterone-induced menstrual cycle in 
amenorrheic patients. Overnight dexamethasone suppression test, if needed, was 
done after taking basal samples and performing OGTT. 
  
ASSAYS: 
 
Radioimmunoassay (RIA) was used to analyse T4, cortisol, 17-OHP, T and 
Immunoradiometric assay (IRMA) for TSH, LH, FSH, PRL using commercial kits in 
duplicate and according to supplier protocol {Diagnostic Product Corporation 
(DPC); USA for LH, FSH, PRL, DIASORIN ;North western Ave for T4 , cortisol  
and IMMUNOTECH; France for T, TSH and 17-OHP}. Plasma glucose (mg/dl) was 
measured by glucose oxidase peroxidase (GOD-POD) method {URILAB; India} 
Cholesterol was measured by CHOD-PAP method {DIALAB; Austria} TG was 
measured by GPO-PAP method {DIALAB; Austria} HDL and LDL was measured 
by New clearance method {RANDOX; UK} on Hitachi 912; Japan. Intra and inter-
assay variations were within the limits permitted by the manufacturer. Plasma levels 
 of s-ICAM, MCP-1, TNF-α, PAI-1 were measured using ELISA kits and factor VIII 
was measured by Coagulometric method.  
Statistical analysis was done using SPSS 11.5 software. In addition to descriptive 
statistics, student’s t test and ANOVA was used to compare the groups. 
 
RESULTS:  
Among 51 women with PCOS without treatment (controls) and 30 women with 
PCOS on OCP’s (cases), number of cycles/year were (9.12±3.88 vs. 9.90±3.30 
P=0.358). Ferriman-Gallwey score was less in OCP treated PCOS subjects compared 
to drug naive (10.00±2.60 versus 12.27±4.71, P=0.017) indicating efficacy of the 
treatment. OCP treated PCOS patients showed increasing marginal rise in clinical 
parameters like weight in Kg (59.07±6.34 versus 58.57±8.52, P=0.782), waist hip 
ratio (0.92±0.06 versus 0.91±0.06, P=0.544) and BMI in Kg/m
2
 (24.07±3.42 versus 
23.66±3.43, P=0.606), systolic BP (123.00±7.21 versus 122.24±6.99 mm Hg, 
P=0.640), diastolic BP (79.46±4.29 versus 79.37±4.62 mm  Hg, P=0.928). Metabolic 
parameters like fasting blood glucose levels were higher in OCP treated   PCOS 
subjects compared to drug naive PCOS subjects (88.77±10.41 versus 87.75±19.91 
mg/dl, P=0.795), as was total cholesterol (186.10±44.76 versus 155.08±28.86 mg/dl, 
P=0.000) and LDL (118.45±45.66 versus 83.20±27.63 mg/dl, P=0.000). Serum 
testosterone level decreased in OCP treated PCOS subjects compared to drug naive 
PCOS subjects (56.05±31.81 versus 63.31±31.30 ng/ml, P=0.320). Fasting insulin 
levels were higher in OCP treated PCOS subjects compared to drug naive PCOS 
subjects (16.23±24.72 versus 12.28±11.10, P=0.326), as was HOMA-IR (3.00±4.17 
versus 2.73±2.64, P=0.335) indicating worsening of insulin resistance with OCP use. 
Accordingly QUICKI was lower in OCP treated PCOS subjects compared to drug 
naive PCOS subjects (0.513±0.013 versus 0.516±0.001, P=0.449). 
Plasma levels of s-ICAM-1 (ng/ml) were higher in OCP treated PCOS subjects 
compared to drug naive PCOS subjects (417.03±131.62 versus 312.41±131.65, 
P=0.001) as were plasma levels of MCP-1(pg/ml) (464.82±91.19 versus 
456.78±187.25, P=0.827) and TNF-α (pg/ml) (25.60±4.24 versus 22.85±5.19, 
 P=0.016) indicting negative impact on various inflammatory markers. Plasma levels 
of procoagulant marker PAI-1(ng/ml) were higher in OCP treated PCOS subjects 
compared to drug naive (1.10±0.59 versus 1.05±0.40, P=0.682) but in contrary 
plasma levels of factor VIII were higher in drug naive compared to OCP treated 
PCOS subjects (0.35±0.33 versus 0.68±0.32, P=0.000). 
CONCLUSION:  
These findings imply that although OCP treatment helps in menstrual cyclicity and 
hyperandrogenism in women with PCOS, metabolic parameters such insulin 
resistance indices, glucose tolerance and lipid profile of PCOS subjects worsens with 
their use. In line with objectives of the present study we observed elevation of 
plasma concentrations of procoagulant (PAI-1) and proinflammatory markers (s-
ICAM, MCP-1, TNF-α) in PCOS subjects treated with OCP’s. Interestingly our data 
did not suggest elevation of factor VIII levels (procoagulant marker) which looks 
intriguing. We don’t have any apparent explanation for this contrary result at this 
moment and the finding needs to be looked at closely and in a systematic way to 
explain it.  Although, we did not have a control group to see the pre-existing 
procoagulant and proinflammatory activity in PCOS women, our data suggests that 
OCP group had unfavorable profile as compared to full blown PCOS women who 
were not treated.  This indicates that E+P use in PCOS women can be viewed as 
unsafe and their routine use may be avoided. More studies with an arm of healthy 
control women on a larger cohort and more detailed   parameters of coagulation and 
inflammation with longitudinal follow up will likely answer the question. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 1 
INTRODUCTION 
  
olycystic ovary syndrome (PCOS) is defined as hyperandrogenic 
chronic anovulation and accordingly women with PCOS have the 
symptoms of irregular menstrual cycles, hyperandrogenism, and polycystic 
enlarged ovaries. PCOS is a heterogeneous metabolic disorder affecting 4 to 
10% of reproductive age women (1). The incidence of PCOS varies 
according to the diagnostic criteria employed. Polycystic ovaries (PCO) on 
ultrasound are noted in up to 25%-30% of reproductive aged women (2,3) 
and the vast majority of women with PCO  do not have the syndrome. 
Women with unexplained hyperandrogenic, chronic anovulation (i.e. NIH 
criteria) make up approximately 7% of reproductive age women (4) while as 
the Rotterdam criterion being broader in view inclusion of sonographic 
evidence of cysts in the ovary increases the prevalence by 50% over the NIH 
criteria (5). The prevalence according to the Androgen Excess Society (AES) 
criteria is somewhere in between. There are no systematic prevalence studies 
from our country however, the condition seems to be very common than 
west and it seems to be on rise in our population. Women with PCOS usually 
present with symptoms of irregular menstrual cycles, acne, hirsutism, 
hyperandrogenism, obesity and enlarged PCO (6). As many as 30% or more 
of women with endocrinologically confirmed PCOS do not have PCO, on 
pelvic ultrasound (7). The genetic contribution to PCOS remains uncertain, 
and there is currently no recommended genetic screening test.  PCOS 
phenotype is likely a complex genetic trait, and based on genome wide 
association studies of such diseases, for example type 2 diabetes, there are 
likely multiple variants. Also no specific environmental substance has been 
identified as a cause of PCOS, although certain medications such as 
valproate have been shown in vitro (8) or in clinical series in women with 
epilepsy to induce hyperandrogenism (9).  As obesity increases its 
prevalence or exaggerates its phenotype, the epidemic of obesity is 
P 
 accompanied by a parallel increase in PCOS prevalence.  In 1935 Stein and 
Leventhal described PCOS as a syndrome characterized by obesity, 
hirsutism and infertility but now the definition of PCOS is controversial at 
best and task of making a positive diagnosis is difficult, thus hampering its 
scientific evaluation (10,11). Besides the pathogenesis of PCOS is complex 
and currently three putative mechanisms have been proposed as follows: 
1. Primary Disordered Gondadotropin Secretion: The first biochemical 
abnormality that was identified in women with PCOS was disordered 
gonadotropin secretion, with a preponderance of luteinizing hormone (LH) 
to follicle stimulating hormone (FSH). This theory explained the 
morphology of the ovary, hirsutism, and anovulation. The excess circulating 
androgen leads to stimulation of the pilosebaceous unit that increases sebum 
production, induces terminal hair differentiation, and in rare instances in the 
scalp leads to pilosbaceous unit atresia and androgenic alopecia.  Studies of 
gonadotropin secretion in women with PCOS have established that women 
have augmented release of LH in response to a GnRH (Gonadotrphins 
releasing hormone) challenge with appropriate levels of FSH secretion (12). 
Obesity tends to blunt baseline LH levels and GnRH stimulated levels in 
women with PCOS, though their response remains elevated when compared 
to appropriate age and weight matched control women (13). 
2. Primary Ovarian and Adrenal Hyperandrogenism: Ovarian 
steroidogenesis is perturbed in the syndrome with increased circulating 
androgen levels. The intrafollicular androgen levels tend to be elevated in 
antral follicles supporting the fact that there is a lack of adequate granulosa 
aromatase activity (14). Thecal cells from PCOS women put into long term 
culture exhibit defects in steroidogenesis including hyper production of 
androgens, possibly a genetic defect in the cells (15). In 20-30% of women 
with PCOS have evidence of adrenal hyperandrogenism, primarily based on 
elevated levels of dehydroepiandrosterone (DHEAS) (an androgen marker of 
 adrenal function), suggesting that the defect in steroidogenesis is primary, 
and affects both androgen secreting glands, i.e. the ovary and the adrenal. 
3. Primary Disorder of Insulin Resistance: Women with PCOS show 
multiple abnormalities in insulin action. Dynamic studies of insulin action, 
including hyperinsulinemic euglycemic clamps and frequently sampled 
intravenous glucose tolerance tests have shown that women with PCOS are 
more insulin resistant than weight matched control women, a defect 
primarily present in skeletal muscle (16,17). Hyperinsulinemia is linked to 
ovarian and adrenal hyperandrogenism in a number of disorders of inherited 
insulin resistance with compensatory hyperinsulinemia including 
leprechaunism, the Rabson Mendenhall syndrome, and the lipodystrophies 
(18). In vitro cultures of PCOS thecal cells have been found to overproduce 
androgens in response to insulin supplementation. 
Thus, PCOS is now recognized to be a variant of metabolic syndrome which 
may include hyperinsulinemia, hyperlipidemia, diabetes mellitus, and 
possibly cardiac disease, as well as the more conventionally recognized 
hirsutism, ovarian follicular atresia with anovulation, infertility, elevated 
androgen levels, endometrial cancer and obesity (19).  Therefore, PCOS now 
should be viewed not just as a gynecological or dermatological disorder, but 
a sex limited manifestation of metabolic syndrome that involves multiple 
body systems and probably stems from a key pathogenic element called 
hyperinsulinemia. There are multiple consensus conferences held so far, for 
purpose of establishing a diagnosis of PCOS. None of them has been good 
enough to withstand various validation techniques. Three main diagnostic 
criteria employed for diagnosis of PCOS are as follows; 
 
 
 
 A. The National Institute Of Health/National Institute Of Child Health 
and Human Development (NIH/NICHHD 1990) consensus conference 
criteria is the most commonly employed diagnosis for the PCOS and is as 
follows 
1. Clinical and/or biochemical hyperandrogenism 
2. Oligo-anovulution(oligomenorrhea/amenorrhea) 
Exclusion of disorders like non-classical congential adrenal hyperplasia 
(NCAH), cushing syndromes, thyroid dysfunction, hyperprolactinemia 
and androgen producing tumors.  
B.  ROTTERDAM 2001 CRITERIA  (20) 
The Rotterdam criteria for the diagnosis of PCOS (2003) states 2 of the 3 
features needs to be present to make the diagnosis and with the exclusion 
of other etiologies (congenital adrenal hyperplasia, androgen-secreting 
tumors, Cushing’s syndrome). These features includes (1) Oligo- or 
anovulation (2) Clinical and/or biochemical signs of hyperandrogenism 
and (3) PCO (either 12 or more follicles measuring 2–9 mm in diameter, or 
an ovarian volume of >10 cm
3
). 
C.  ANDROGEN EXCESS SOCIETY(AES) (21) 
Diagnostic criteria lead down by (AES 2006) includes hyperandrogenemia 
and or hyperandrogenism plus one out of 2 remaining criteria of 
oligo/amenorrhea and polycystic ovaries on ultrasonography. 
Obesity is the major accompaniment in 30-60% of the women with PCOS 
(22). Obesity promotes an unconventional, sub-clinical inflammation, mainly 
due to secretion of a battery of pro-inflammatory factors [e.g. Leptin, TNF-α, 
IL-6, IL-1β] (23,24). The proinflammatory nature of adipose tissue is 
heightened in proportion to fat accumulation and exhibits consistent positive 
correlations with increasing body mass index (BMI) and especially with 
visceral adiposity (23,24,25). Thus, central obesity appears to trigger and 
exacerbate an inflammatory cascade that initially evolves within fat depots. 
 Indeed, current evidence suggests that this obesity-related activation of 
inflammatory signaling pathways is linked to major cardio vascular disease 
(CVD) risk factors [e.g.  Type 2 diabetes (T2DM) and atherosclerosis] 
(26,27). Obesity also induces multiple constitutional alterations in the micro-
environment and cellular content of adipose tissue depots which collectively 
promote differentiation of pre-adipocytes, insulin resistance and 
proinflammatory responses (23,24). Weight gain enhances both lipogenesis 
and adipogenesis inside fat depots, as well as secretion of proinflammatory 
adipokines and chemokines [e.g. MCP-1, and IL-8] into the plasma. In 
response to such chemotactic stimuli mononuclear cells are recruited from the 
circulation and transmigrate into adipose tissue depots, increasing the number 
of resident macrophages (28,29). In turn, this growing local population of 
macrophages secretes cytokines, such as TNF-α, IL-1β and IL-6, which can 
potentially aggravate the proinflammatory and insulin resistant profile of 
adipocytes. Thus, sustained fat accumulation establishes an unremitting local 
inflammatory response within the expanding adipose tissue. Progressively this 
cascade transcends to a chronic low-grade generalized inflammatory state in 
obesity, mediated by persistent release of proinflammatory adipokines of 
either adipocyte or macrophage origin (30) with adverse effects on peripheral 
tissues and organs (e.g. liver, muscles, endothelium). These effects promote 
hepatic and skeletal muscle insulin resistance, hypertension, atherosclerosis 
and hypercoagulability. In fact, subclinical CVD and early impairment of 
endothelial structure and function have been previously reported in non-obese 
PCOS women (31-35). Insulin resistance has been associated with an 
increased incidence of CVD as atherosclerosis is now considered to be an 
inflammatory disorder (36,37).  
Insulin resistance has recently been associated with increased levels of 
inflammatory mediators in the blood (38, 39). Studies have therefore been 
conducted to look at inflammation in PCOS.  TNF-α has been shown to play 
 an important role in initiation of inflammation (40). The TNF-α signaling 
pathway is mediated by nuclear factor kappa B (NF-KB) and is responsible for 
the expression of adhesion molecules such as soluble vascular cell adhesion 
molecule-1 (sVCAM-1) and soluble Intercellular adhesion molecule-1 
(sICAM-1) in the endothelium (41). Gonzelez et al noted increased levels of 
TNF-α, the cytokine which causes insulin resistance and is secreted by the 
adipose tissue in PCOS women as compared to controls (42). 
As is generally accepted that atherosclerosis is an inflammatory disease, the 
initiating factor is considered to be endothelial dysfunction (43, 44). This is 
followed by inflammatory cell infiltration and lipid accumulation; which in 
turn stimulate vascular smooth muscle cell proliferation, migration and extra-
cellular matrix production. Normally, the vascular endothelium resists the 
binding of leucocytes, presenting a barrier to their infiltration into the sub-
endothelial layer. However, a variety of stimuli may impair endothelial 
function, rendering it susceptible to leucocyte adhesion, and potentially 
initiating atherogenesis. Similar processes are also implicated in the acute 
manifestations of atherosclerosis (45). The predominant mechanism in the 
pathogenesis of the acute coronary syndromes is atherosclerotic plaque 
rupture. Histological evidence confirms that this is characterized by 
infiltration of leucocytes.  These release proteolytic enzymes that weaken the 
extracellular matrix destabilizing the plaque, and increasing the risk of 
exposure of its thrombogenic sub endothelial matrix and lipid core. 
Endothelial erosion, a less common but important cause of unstable 
atherosclerotic disease, particularly in younger patients, is also associated with 
dysfunction and destruction of endothelial cells (46). Once again the adhesion 
of leucocytes is a fundamental component of this process. The binding of 
leucocytes to vascular endothelium is mediated by a variety of cell surface 
adhesion receptors–principally the selectins and integrins. The selectins are 
the initiators of adherence, but the binding they induce is weak, allowing 
 leucocytes to roll along the vessel wall. This contact enables leucocyte and 
endothelial integrins to interact, permitting the more secure binding that 
precedes spreading and infiltration. The main endothelial integrin receptors 
sVCAM-1 and sICAM-1, which bind to leucocyte β 1 (α4β1) and β2 (αLβ 2 
and αMβ 2) integrins, respectively. Normal vascular endothelium expresses 
little or no sVCAM-1 or sICAM-1.  They are, however, induced by 
endothelial dysfunction, suggesting that they may represent biological 
'markers' of atherosclerosis and might predict an increased risk of its acute 
manifestations. Certainly, focal endothelial sVCAM-1 and sICAM-1 have 
been demonstrated overlying areas of early atherogenesis (47, 48) and within 
atherosclerotic plaques (49-51). Several data support the hypothesis that 
soluble cell adhesion molecule levels may reflect the extent of atherosclerotic 
disease. Patients with CVD or peripheral vascular disease have higher levels 
of sICAM-1 than healthy controls (52). Likewise, several large 
epidemiological studies have demonstrated that apparently healthy subjects 
with elevated levels of sICAM-1 are at increased risk of developing overt 
coronary artery disease (CAD), peripheral vascular disease, carotid 
atherosclerosis and stroke (53-58). As Rizzoni and colleagues report, many 
risk factors for atherosclerosis, including diabetes and hypertension, are 
generally (though not always) associated with increased levels of sICAM-1 
and sVCAM-1 (59-66). It is unclear whether the observed elevations are 
because of direct effects or to subclinical atherosclerosis. Certainly, elevated 
levels of both sICAM-1 and sVCAM-1 have been documented in patients with 
essential hypertension without overt atherosclerotic disease (63) although in 
this cohort of elderly (mean age 69 years) hypertensive men, it seems likely 
that some would have in apparent disease. The data from Rizzoni et al (59) 
showing significant elevations of sICAM-1 and sVCAM-1 in patients with 
hypertension and normal intima–media thickness, do, however, suggest that 
hypertension may play a direct role. In PCOS, significantly higher levels of 
 sICAM-1 than in healthy women were found. sICAM-1 levels correlated with 
body composition, lipids and insulin secretion, but not with insulin resistance 
(67). 
Women with PCOS are characterized by increased levels of procoagulant 
markers like fibrinogen and PAI-1 both of which promote atherogenic 
processes and increase the risk of CVD (68-71). Fibrinogen is synthesized by 
hepatocytes and holds a pivotal role in the coagulation cascade, being a major 
determinant of plasma viscosity and platelet aggregation. Expression of 
fibrinogen in the liver is up-regulated by IL-6 during the acute phase reaction 
and various studies have documented an association between elevated 
fibrinogen levels and increasing body mass index (BMI).  Notably, fibrinogen 
has also been shown to predict weight gain in middle-aged adults (72). PAI-1 
levels are increased in various disease states (some forms of cancer, obesity 
and the metabolic syndrome has been linked to the increased occurrence of 
thrombosis in patients with these conditions. In inflammatory conditions 
where fibrin is deposited in tissues, PAI-1 appears to play a significant role in 
the progression to fibrosis (pathological formation of connective tissue). 
Presumably, lower PAI levels would lead to less suppression of fibrinolysis 
and conversely a more rapid degradation of the fibrin. Women with PCOS 
may have an imbalance in the plasminogen activator system that is tilted 
toward a reduced production of the proteolytic enzyme plasmin. Systemically, 
this may increase their risk of CVD but at cellular level in the ovaries, it may 
result in impaired follicular rupture and anovulation (73). Glueck et al 
demonstrated that PAI-1 activity was an independent risk factor for 
miscarriages in PCOS (74). PAI-1 regulates the endogenous fibrinolytic 
system and constitutes the main inhibitor of fibrinolysis by binding and 
inactivating the tissue plasminogen activator (tPA), thus increased PAI-1 
activity leads to decreased clearance of clots. Elevated PAI-1 levels have been 
associated with increasing BMI and visceral adiposity, as well as with 
 metabolic syndrome components (75-78). Thus, obesity especially abdominal 
adiposity influence the abnormalities in blood coagulation found in PCOS 
patients, as has been also demonstrated for many other CVD risk factors 
frequently associated with this prevalent disorder (79,80). Data in young 
PCOS subjects suggest that it is not only associated with abnormalities in 
fibrinolysis (81), but also with thrombophilia in conceptual agreement with 
the effect of insulin resistance on coagulation previously reported in the 
general population (82).  
High factor VIII levels are a common risk factor for venous thrombosis (83-
85) and may also be associated with the risk of arterial thrombosis in CAD 
(86,87) and stroke (88).  The regulation of plasma factor VIII levels is 
complex. Most factor VIII circulates as a complex with von Willebrand factor 
(vWF) (89,90) the levels of which are known to be dependent on factors such 
as blood group (91-93) and endothelial stimulation (94,95). After its activation 
by thrombin, factor VIIIa dissociates from vWF to form a complex with factor 
IXa, which will result in marked acceleration of the activation of factor X 
(96). Activated factor X then converts prothrombin into thrombin, which in 
turn converts soluble fibrinogen into insoluble fibrin. It is possible that high 
factor VIII levels just increase the rate of thrombin and fibrin formation (in 
plasma, there is a large molar excess of factor IX over factor VIII). Another 
possibility is that high factor VIII levels influence thrombotic risk via an effect 
on the activated protein c sensitivity ratio (APCR). It has been shown that (in 
the absence of factor V Leiden) the thrombosis risk for the lowest quartile of 
normalized APCR (0.92) is 4.4-fold higher than that for the highest quartile 
{1.05}(97). For these measurements, “first generation” APC-resistant tests 
were used (no dilution of the sample with factor V–deficient plasma). This 
explains the finding that high factor VIII levels are associated with a reduced 
sensitivity for APC in the absence of factor V Leiden (98-100). After 
adjustment for factor VIII levels, the thrombosis risk associated with a 
 normalized APCR, 0.92 fell from 4.4- to 2.5 fold, indicating that factor VIII 
has a strong confounding effect on the thrombosis risk of a low APC ratio. 
Vice versa, it is also possible that high factor VIII exerts a thrombotic risk 
through the associated decreased responsiveness to APC. BMI (positively 
correlated with factor VIII levels) and higher levels of glucose, insulin, 
fibrinogen, and triglycerides are also associated with increased factor VIII 
levels (87,101,102). 
The underlying etiology of PCOS remaining elusive, most of the therapeutic 
approaches in the past would focus on inhibiting or decreasing androgen 
production by various modalities {ovarian wedge resection, laproscopic 
ovarian drilling, LHRH (leutinizing hormone releasing hormone) analogues, 
aromatase inhibitors, estrogen-progesterone combinations, or anti-androgens} 
(103-109). The antiandrogen, spironolactone, a steroid chemically related to 
mineralocorticoid, aldosterone is used as a diuretic as well as antiandrogen 
(110, 111). Dual blockade by spironolactone anti-androgen and synthesis 
inhibitor (112,113), makes it suitable for long term treatment of 
hyperandrogenism (primarily hirsutism) and an-ovulation (114,115,117,118). 
Although the experience of spironolactone in PCOS is limited, it has a good 
safety record when used in smaller doses (117-122). The drug has been used 
as a sole agent, in combination or in head to head comparison with other 
agents (114, 117, 122-123). Treatment of PCOS by insulin sensitizers, like 
thiazolidinediones and   metformin has generated significant interest in recent 
years, keeping in view the fundamental pathogenic factor of insulin resistance. 
Metformin has also been shown to directly inhibit human thecal cell androgen 
synthesis, suggesting an insulin independent mechanism (123-126). Many 
publications have demonstrated the efficacy of metformin in improving 
menstrual cyclicity, metabolic parameters, ovulation, cervical scores, and 
pregnancy outcomes both spontaneous and assisted (127-144). Among many 
metanalysis using metformin the results were favourable (145-147). In the 
 recent metanalysis of 27 trials using metformin involving 2150 women 
authors concluded that although metformin does not improve live birth rate 
but improves clinical pregnancy and ovulation rates (148). Other insulin 
sensitizers alone in combination with anti-androgens have been used with 
variable success (149-152). 
In the chronic treatment of PCOS, OCP’s are commonly used to induce 
regular menstrual cycle, protect the endometrium and ameliorate androgenic 
symptoms. OCP’s typically contain the estrogen component (ethinyl estradiol) 
or its precursor mestranol which is metabolized into ethinyl estradiol and a 
progestin component which is variable according to the preparation (153). 
Estrogen component (ethinyl  estradiol) of  OCP’s has a role in suppression  of 
FSH, stabilization of endometrium, potentiation  of progestin action, 
suppression of dominant follicle formation, increase in sex hormone binding 
globulin (SHBG)  and decrease in free androgen (154). Progestin component 
has a role in suppression of LH, inhibition of LH surge, unreceptive 
endometrium, hostile cervical mucus, decrease in ovarian androgen secretion 
and androgen blocking effect (155).  
 
The OCP’s are categorized according to when they were approved or 
introduced as follows: 
 
First generation;          Norethindrone,  Norethindrone acetate.  
 
Second generation;      Norgestrel,  Levonorgestrel, Ethynodiol diacetate.  
 
Third generation;        Norgestimate,  Desogestrel.  Others Drospirenone, 
Dienogest (156). 
 
 The commercially available OCP’S in India are given in a following table: 
Estrogen (µg)      Progestin (mg)   Commercial name 
Ethinyl estradiol  (35) Norethindrone (1) Orthonovum1/35,Necon 1/35 
Ethinyl estradiol  (35) Norethindone (0.4) Ovcon 35 
Ethinyl estradiol  (35) Ethynodiol (1) Demulen 1/35 
Ethinyl estradiol(35)   Norgestimate (0.25) Orthocyclen 
 Ethinyl estradiol ( 30) Norethindrone (1.5) Loestrin 21 1.5/30 
Ethinyl estradiol  (30)   Norgestrel (0.3) Lo-ovral 
Ethinyl estradiol(30)     Desogestrel (0.15) Desogen, Marvelon 
Ethinyl estradiol (30)    Levonorgestrel (0.15) Levlen, Nordette 
Ethinyl estradiol (30)    Gestodene (0.075) Gynera, Minulet 
Ethinyl estradiol (30)     Drosperinone (3) Yasmin, yamini 
 Ethinyl estradio ( 20) Norethindrone (1) Loestrin 21 (1/20) 
Ethinyl estradiol  (20)  Levonorgestrel (0.1) Alesse, Levlite 
Ethinyl estradiol   (20) Desogestrel (0.15) Mircette, Mercilon 
Ethinyl estradiol(20)   Gestodene (0.075) Meliane, Harmonette 
Ethinyl estradiol   (20)  Drosperinone (3) Yaz 
Ethinyl estradiol  15 Gestodene (0.06) Melodia 
 
PCOS women treated with OCP’s have a lower incidence of ovarian cysts, 
and ovarian volume decreases with their use (157,158). OCP’s decrease the 
body's   production of androgens, which can reduce and slow hair growth and 
acne (159-160). Although there are some positive benefits of OCP use in 
women with PCOS, some of the disadvantages may contribute to the 
worsening of the disease process, which include   increase in insulin 
resistance, blood coagulation, total cholesterol, low density lipoprotein (LDL) 
cholesterol, high density lipoprotein (HDL) cholesterol levels and 
triglycerides (TG) with no change of the total cholesterol/HDL cholesterol and 
LDL cholesterol/HDL cholesterol ratios (161-166). OCP’s increase the risk of 
venous thrombo embolism including deep vein thrombosis (DVT) and 
pulmonary embolism (PE),risk of first ischemic stroke and current use 
 significantly increases the risk of cardio-vascular disease among those at high 
risk (167-169). Women taking third generation OCP’s had significantly higher 
C-reactive protein, fibrinogen, plasma viscosity, and HDL-cholesterol 
concentrations compared   to non-users. Potentially harmful effects of OCP’s 
may arise from their positive association with the acute phase response. There 
is a close relationship with inflammatory markers in particular in women 
taking third generation OCP’s, which may, at least in part, contribute to the 
increased atherothrombotic risk, reported specifically in these women (170). 
Therefore pro-inflammatory state and a prothrombic / pro-coagulant state are 
individually a cause of concern in PCOS women using OCP’s. Thus 
conventional treatment with OCP’s may worsen the already existing   
procoagulant and proinflammatory state indicating higher cardiovascular risk 
in these women. In view of the above, we plan to study procoagulant markers 
and proinflammatory markers, in drug naive PCOS women and compare them 
with PCOS women treated with OCP’s for varying duration of time that will 
help to know about the impact of OCP’s on the existing CVD risk in PCOS 
women.  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 2 
 
REVIEW  
OF 
LITERATURE  
  
n 1921 Archard and Thiers published a famous report of the “bearded 
diabetic women” pointing towards the association between glucose 
intolerance and hyperandrogenism.  Since then glucose intolerance and insulin 
resistance has been intensively studied among the metabolic abnormalities 
(171). 
First to report PCOS in 1935 was published by Stein and Leventhal. Since 
then, its prevalence data has remained variable because of the lack of well-
accepted criteria for diagnosis. PCOS prevalence as per previous studies was 
mostly based on the demonstration of histopathological evidence of polycystic 
ovaries upon oophorectomy or wedge resection by Goldzieher and Green 
(1962) had shown presence of corpus luteum in 16% of surgical specimens 
(172).  
Ferriman and Gallwey in 1961 did assessment of hirsutism in a systematic 
manner first time when they  scored density (0-4)  of hair in 11 body  areas 
(upper lip, chest, upper back, sacrum, upper back, upper abdomen, lower 
abdomen, arm, forearm, thigh and lower leg) in 161 women aged 18-38 years 
(430 control women  aged 15-74 years). They found a score of 5, 7 and 10 was 
respectively found in 9.9%, 4.3% and 1.2%. They also concluded that forearm 
and lower leg areas were less sensitive (173). 
Peterson in 1973 in a Swedish population-based study estimated that 4.4 % of 
female population had a secondary amenorrhea of more than 3 months 
duration (174). 
In 1976 Kahn and colleagues reported the existence of severe insulin 
resistance and acanthosis nigricans in three lean adolescent women. This type 
of insulin resistance soon became known as type A syndrome-similar to what 
is called as HAIR-AN syndrome (hyperandrogenism, insulin resistance and 
acanthosis nigricans)(175). 
I 
 In 1980 Burghen and colleagues reported that women with PCOS have basal 
and glucose-stimulated hyperinsulinemia compared to weight-matched 
(control) women. They noted significant positive linear correlation between 
insulin and androgen levels in plasma (176). 
Hatch R et al in 1981 suggested a simplified scoring system including only 
four important areas of assessment viz. sideburn area, lower jaw, upper neck, 
and buttocks (177). 
Evans D J et al in 1983 showed the android type of obesity is associated with 
insulin resistance, glucose intolerance and atherogenic lipid profile in PCOS 
and was attributed to hyperandrogenism (178). 
Penttila IM et al in 1983 measured lipid and protein levels in serum of healthy 
women during treatment with a new OCP combination .Treatment lasted for 3 
months. At the end of treatment the serum total cholesterol, HDL-cholesterol 
and TG was increase in all women. Also lipid and protein levels returned to 
initial levels 2 months after treatment stopped (179). 
Wild et al in 1985 demonstrated that the lipid abnormalities consisting of high 
total cholesterol, high LDL, high TG   and lower HDL in PCOS females 
(180). 
Dalhgren et al in 1985 reported that the lipid derangements and obesity in 
polycystic ovary syndrome patients as expected should increase the 
cardiovascular risk (181). 
Orisni L et al in 1985 also studied ultrasound in the diagnosis of PCOS and 
suggested its clinical relevance (182). 
Mathews D R et al   in 1985 devised model for quantitating insulin resistance 
by Homeostatic model assessment for insulin resistance (HOMA) (183). 
Cullberg G et al in 1985 performed lipid metabolic studies in women with 
PCOS during treatment with low dose desogestrel-ethinylestradiol (EE) 
combination. They found that only moderate changes were induced in lipid 
and lipoprotein patterns by the combination of desogestrel and EE (184). 
 Mauvais-Jarvis P et al in 1986 said the common areas affected are face and 
chin with a tendency towards male escutcheon. This is related to high levels of 
serum androgens or increased local skin 5-α reductase activity or both (185). 
Dunaif et al  in 1987 found that obese women with PCOS had significantly 
increased glucose values during an OGTT compared to age and weight 
matched ovulatory hyperandrogenic and control women. Twenty percent of 
obese women with PCOS had impaired glucose tolerance or frank type 2 DM 
by National Diabetes Data Group (NDDG) criteria (186). 
Polson et al in 1988 conversely said that many patients with clinical evidence 
of PCOS may not demonstrate cysts in the ovaries (187). 
Robinson GE et al in 1990 studied changes in metabolism induced by oral 
contraceptives desogestrel and gestodene in older women. Women taking the 
combined pill showed increases in fibrinogen and factor X and a reduction in 
antithrombin III when compared with their control values. There were also 
small but significant increases in triglycerides and triglyceride-rich 
lipoproteins. These changes in lipids and lipoproteins would not appear to 
increase the risk of cardiovascular disease; however the effects of the increase 
in the pro-coagulant factors are uncertain (188). 
Wild R A in 1990 et al in a small study reported higher prevalence of coronary 
artery disease due to clinical excess of androgens (189). 
Dahlgren et al in 1992 have calculated via a risk model analysis that patients 
with PCOS had a 4 to 7-fold higher risk of myocardial infarction compared to 
age matched controls. In a study of 143 women undergoing cardiac 
catheterization, aged 60 years or younger, PCOS was detected in 42% of 
women on pelvic ultrasonography. Patients with PCOS exhibited coronary 
artery segments with >50% stenosis with significantly greater clinical heart 
disease  than women with normal ovaries on ultrasonography (190).  
Talbott and coworkers in 1995   reported lipid abnormalities consisting of high 
total cholesterol, high LDL, high TG   and lower HDL in PCOS females. They 
 also observed that these lipid abnormalities persisted on adjusting for BMI 
(191). 
Quehenberger P et al in 1996   studied the effect of OCP treatment on selected 
factors involved in the activation i.e. circulating activated factor VII (cFVIIa), 
and in the inhibition of blood coagulation, i.e. plasma protein S activity and 
circulating thrombomodulin (cTM). They reported the increased level of 
activated factor VII and decreased plasma protein S activity and circulating 
thrombomodulin during use of oral contraceptives (192). 
Solomon CG in 1998 showed that the menstrual disturbances in the form of 
irregular and unpredictable uterine bleed attributed to unopposed estrogen 
mediated endometrial proliferation are common. In amenorhoeic females it 
has been estimated that about 30-40% may actually have PCOS (193). 
Bloemenkamp KW et al in 1998   investigated 99 pre-menopausal women, age 
15-49 years, who had used OCP at the time of a first, objectively confirmed 
episode of deep-vein thrombosis (DVT). The following hemostatic variables 
were measured: APTT, factor VII, factor VIII, factor XII, fibrinogen, 
prothrombin, total antithrombin, normalised activated protein C sensitivity 
ratio (n-APC-sr), protein C, protein S and free protein S.  They found marked 
and significant effects of oral contraceptive use on the levels of several 
clotting factors, with an increase in factor VII, factor XII, protein C and a 
decrease in antithrombin, n-APC-sr and protein S (166). 
Gonzalez F et al in 1999 in a study was undertaken to determine the status of 
circulating TNF-α and the relationship of TNF-α with insulin levels, body 
weight, or both in women with PCOS. They conclude that  serum TNF-α is 
increased in normal-weight women with PCOS and is even higher in obese 
individuals regardless of whether they have PCOS; factors other than obesity 
are the cause of elevated serum TNF-α in normal-weight women with PCOS; 
and  whereas increased circulating TNF-α may mediate insulin resistance in 
obesity, which may in turn promote hyperandrogenism in obese women with 
 PCOS, it remains to be demonstrated whether this is also the case in normal-
weight women with PCOS (194) 
Van Rooijen M et al   in 2002 compared the effects of two different combined 
OCP on levels of plasma lipoproteins and coagulation factor VII. A significant 
rise in plasma triglyceride levels was obtained with both preparations, 
although the increase was more pronounced with ethinyl estradiol/desogestrel. 
Plasma concentrations of factor VII and activated factor VII were increased 
significantly only with ethinyl estradiol/desogestrel than with ethinyl 
estradiol/levonorgestrel (195). 
Sundararaman PG et al in 2003 reported the increased risk of atherosclerosis 
in women with PCOS. They conducted a cross-sectional case control study, 
they assessed insulin resistance and carotid IMT (Intima media thickness) in 
40 women presenting with hyper androgenic features of PCOS. Insulin 
resistance was assessed by fasting glucose/insulin ratio and IMT by the 
doppler system with electrical linear transducer midfrequency of 12 MHz 
Women with PCOS had higher fasting insulin levels, higher insulin resistance 
and greater IMT. They concluded that South Indian women with the 
reproductive abnormalities of PCOS have greater insulin resistance and IMT, 
and therefore they must be advised about lowering the risk of future vascular 
disease (196). 
Ganie MA et al in 2004 in a study carried out to estimate the prevalence of 
glucose intolerance and insulin sensitivity in young women with PCOS 
examined 168 young women who attended AIIMS endocrine center for 
hirsutism and / or oligomenorrhea were enrolled for the study.  NICHHD 
consensus conference criteria were used for diagnosis of PCOS.  Results 
indicated higher prevalence glucose intolerance even at younger age in PCOS 
females (197).  
Ganie MA et al in 2004   on comparison of efficacy of spironolactone with 
metformin in the management of PCOS found that spironolactone appears 
 better than metformin in the treatment of hirsutism, menstrual cycle frequency 
and hormonal derangements and is associated with fewer adverse events 
(198). 
Vrbikova J, Cibula D in 2005 suggested that common oral contraceptives 
(COC’s) are the primary treatment for contraception and regulation of menses 
in women with PCOS. COC’s also offset the effect of estrogen on the 
endometrium and improve acne, hirsutism and oligomennorhea (199). 
In a recent study Apridonidze et al in 2005 hypothesized that the metabolic 
syndrome is prevalent in PCOS and those women with both conditions will 
have more hyperandrogenism and menstrual cycle irregularity than women 
with PCOS only .Women with PCOS and the metabolic syndrome had 
significantly higher levels of serum free testosterone and lower levels of 
serum SHBG than women with PCOS without the metabolic syndrome. No 
differences in total testosterone were observed between the groups. They 
concluded that the metabolic syndrome and its components are common in 
women with PCOS, placing them at increased risk for cardiovascular disease 
(200). 
J Vrbikova et al in 2005 reported   significantly higher levels of ICAM-1 than 
in healthy women were found. ICAM-1 correlated with body composition, 
lipids and insulin secretion, but not with insulin resistance (67).  
EvanthiaDiamanti-Kandarakis et al in 2006 reported higher plasma levels of 
hs-CRP(mg/l), SICAM-1, E-slectin in  PCOS  compared to the 
controls.VCAM-1 did not differ significantly in two groups. Significant 
reduction in VCAM-1 and hs-CRP was achieved after 6 months of metformin 
administration .These findings imply the presence of chronic inflammation in 
women with PCOS. Metformin decreased the level of plasma inflammatory 
indices (201). 
Anuradhakalra et al in 2006 in the prospective study calculated the body mass 
index (BMI) and waist hip ratio of 65 women with PCOS. Fasting glucose, 
 insulin and lipid profiles were also estimated in each case. Insulin resistance 
was defined by fasting glucose-to-insulin ratio £ 4.5. The association of 
obesity markers and insulin resistance with lipid parameters was 
thenstudied.They reported insulin resistance is associated with dyslipidemia in 
women with PCOS independent of obesity (202). 
E. Diamanti-Kandarakis et al in 2006 conducted a study to investigate the 
coexistence of active inflammation markers and endothelial dysfunction in 
young women with PCOS, and their relationship with metabolic and hormonal 
abnormalities of the syndrome. They concluded that PCOS patients had 
statistically higher levels of endothelin 1(ET-1), sICAM-1, sVCAM-1 
andhsCRP (P = 0·01). This study demonstrates that endothelial dysfunction 
coexists and is influenced by the presence of increased serum levels of 
inflammation and endothelial activation markers in young women with PCOS. 
These parameters appear to be interrelated with hyperandrogenaemia in this 
insulin-resistant population (203). 
Ganie MA et al in 2008 showed that there is the high prevelance of PCOS 
characteristic in girls with euthyroid chronic lymphocytic thyroiditis (204). 
Kulshreshtha B etal in 2008 reported that women with PCOS had an 
exaggerated insulin response to glucose (205). 
Luque Ramirez M et al in 2009 compared the effects of anti- androgenic OCP’s 
with metformin on blood coagulation tests and endothelial function in women 
with PCOS as a function of presence of obesity and smoking. They concluded 
that  oral contraceptives and metformin may exert deleterious effects on blood 
clotting tests of PCOS women, yet the effects of metformin appears to be 
milder. As smoking potentiates some of these effects and deteriorates 
endothelial function, smoking cessation should be promoted in PCOS patients 
and the possible adverse impact of OCP’s on the already unfavorable 
prothrombotic state of PCOS patients should be considered (206). 
 Scholes D et al in 2010 reported that prolonged use of today's OCPs, 
particularly <30 mcg EE, may adversely impact young adult women's bone 
density while using these agents. They conducted a  cross-sectional study of 
606 women aged 14-30 years, examined both OCP duration and estrogen dose 
and their association with bone mineral density (BMD) at the hip, spine, and 
whole body (dual-energy X-ray absorptiometry).They found  that among  389 
OCP users and 217 nonusers enrolled, 50% were adolescents (14-18 years). Of 
OCP users, 38% used "low-dose" OCP’s [<30 mcg ethinyl estradiol (EE)]. In 
adolescents, mean BMD differed by neither OCP duration nor EE dose. 
However, 19- to 30-year-old women's mean BMD was lower with longer OCP 
use for spine and whole body (p=.004 and p=.02, respectively) and lowest for 
>12 months of low-dose OCP for the hip, spine and whole body (p=.02, .003 
and .002, respectively) (207). 
Kriplani A et al in 2010 conducted a prospective randomized trial to compare 
efficacy of a drospirenone-containing combined oral contraceptives (COC) 
with desogestrel-containing COC in women with PCOS not desirous of child-
bearing.  Sixty women were randomized into study group [ethinylestradiol 
(EE) 30 mcg+drospirenone 3 mg] and control group (EE 30 mcg+desogestrel 
150 mcg), treated for 6 months and followed up at 1 month, 3months, 6 
months, during treatment and 3 and 6 months post-treatment. They reported 
that in women with PCOS, a drospirenone containing COC has better outcome 
in terms of persistent regular cycles, anti-androgenic effect, fall in BMI and 
BP, better lipid profile, favorable glycaemia and hormonal profile than 
desogestrel-containing COC (208). 
Halperin et al in 2011 studied the association between the COC and insulin 
resistance, dysglycemia and dyslipidemia in women with PCOS and concluded 
that COC use was significantly associated with an increase in HDL-C and 
triglycerides. Significant heterogeneity was found in glucose, cholesterol, 
 HDL-C, LDL-C, triglycerides, fasting glucose to insulin ratios and homeostatic 
model assessment –IR (209). 
Kilic et al in 2011 in a study to evaluate the optimal treatment strategy 
addressing cardiovascular risk in obese and non-obese patients with PCOS 
concluded that metformin treatment leads to improvement in hormonal and 
metabolic parameters and decreases asymmetric dimethyl arginine (ADMA) 
and homocysteine levels possibly independent of BMI. However, the use of 
oral contraceptives in obese and non-obese patients with PCOS with impaired 
glucose tolerance increases ADMA and hs-CRP levels and creates an increase 
in the metabolic risk (210). 
Ekaterini Koiou et al in 2012 evaluated PAI-1 antigen levels in women with 
PCOS and different levels of adiposity and PCOS phenotypes. They studied 
199 women with PCOS and 50 age-matched healthy women divided in normal 
weight (n=100 and n=25, respectively) and overweight/obese (n=99 and n=25, 
respectively). Normal weight and overweight/obese patients with PCOS were 
further divided in patients diagnosed according to the 1990 criteria (i.e. with 
anovulation and hyperandrogenemia; 1990 criteria group) and in patients with 
the additional phenotypes introduced in 2003 (i.e. with polycystic ovaries and 
either anovulation or hyperandrogenemia; additional 2003 criteria group). In 
normal weight subjects, plasma PAI-1 levels did not differ between women 
with PCOS (regardless of group) and controls, or between the 1990 criteria 
and the additional 2003 criteria groups of PCOS. In overweight/obese 
subjects, plasma PAI-1 levels were higher in both the 1990 criteria and the 
additional 2003 criteria groups of PCOS compared with controls (p<0.001 and 
p=0.004, respectively), but did not differ between the 1990 criteria and the 
additional 2003 criteria groups of PCOS. In conclusion, plasma PAI-1 levels 
are elevated in overweight/obese women with PCOS but not in normal weight 
women with this syndrome. Plasma PAI-1 levels do not differ between the 
phenotypes of PCOS (211). 
  
  
Chapter 3 
 
AIMS 
& 
OBJECTIVES  
  
 
 
o study and compare the levels of following procoagulant and the 
proinflammatory markers 
 
1. Tumor necrosis factor α (TNF-α). 
2. Soluble Intercellular cell adhesion molecule-1 (sICAM-1). 
3. Antihaemophilic factor (Factor VIII). 
4. Plasminogen activator inhibitor-1 (PAI-1). 
5. Monocyte chemo attractant protein-1 (MCP-1). 
in drug naive and OCP treated women with PCOS. 
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Chapter 4 
MATERIALS  
& 
METHODS   
 4.1 MATERIALS & METHODS: 
4.11     History and general examination 
All women who qualified Rotterdam 2003 criteria for a diagnosis of PCOS 
were informed about the study. The first step was consent attainment. The 
women who gave informed consent were enrolled in the study. Once enrolled 
all women were interviewed to furnish a detailed account of medical facts 
with   special reference to the menstrual history, duration and extent of hair 
growth, weight gain, acne etc. The details of menstrual history included age of 
menarche, regularity, duration, dysmenorrhea, flow and number of menstrual 
cycles per year. Oligomenorrhea was defined as an inter-menstrual interval of 
>35 days or a total of <8 menses per year and amenorrhea as absence of 
menstruation   during last 6 months. Note was made of family history of 
hirsutism, infertility, menstrual disorders, diabetes mellitus or glucose 
intolerance, coronary artery disease and obesity at least in three generations. 
The subjects were randomly selected from the two categories: 
1. Cases - The women taking OCP’s (estrogen + progesterone) from 
various gynecology clinics for the treatment of Rotterdam 2003 
criterion based PCOS diagnosis. The women had been taking OCP’s for 
a period of 24 + 2 weeks was taken as cases. 
2. Controls – The women who qualified Rotterdam 2003 criteria for 
diagnosis of PCOS and had not received any drug so far were taken as 
control group. All these women who consented were subjected to a 
positive diagnostic criterion as follows: The Rotterdam criteria for the 
diagnosis of PCOS (2003) states 2 of the 3 features needs to be 
present to make the diagnosis and with the exclusion of other 
etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, 
Cushing’s syndrome). These features includes (1) Oligo- or anovulation 
(2) Clinical and/or biochemical signs of hyperandrogenism and (3) PCO 
 (either 12 or more follicles measuring 2–9 mm in diameter, or an 
ovarian volume of >10 cm3. Non classic adrenal hyperplasia (NCAH), 
Cushing’s syndrome, thyroid dysfunction, hyperprolactinemia, and 
androgen-producing tumors will be ruled out by doing relevant 
investigation.  
4.12       Physical examination 
 All women underwent anthropometric assessment like measurement 
of height, weight, waist-hip circumference ratio, blood pressure 
recording, and detailed systemic examination. Hirsutism assessment 
was done using modified Ferriman-Gallwey score by counting nine 
specified body areas (Pic A).  A score of > 8 out of a total of 36 will be 
taken as significant (Pic A1). 
 
HIRSUTISM SCORING   
Modified Ferrima-Gallwy method 1960 
Each area =1-4 
Total score =36   Significant >8 
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Pic A1 
 Acne vulgaris will be scored using a four point scale :0,no 
acne:1,minor acne on face only:2,moderate acne on face 
only:3,severe acne on face, back and or chest. Moderate to 
severe acne was taken as a clinical feature of 
hyperandrogenemia (Pic A2).    
 
 
 Pic A2 
 All patients were subjected to transabdominal ultrasonography 
(USG) by a single observer. The USG was done to measure and 
to record typical features of PCOS (multiple small peripheral 
cysts, increased ovarian volume and thecal hyperechogenecity) 
and to rule out any adrenal or ovarian mass lesion (Pic A3). 
 
 
 
 
 
 
 
 
Pic A3 
            4.13 Investigations and assays 
On the day of study, a fasting (10-14 hour) blood samples were taken 
for 
 Triglycerides (TG) 
 Low density lipoprotein (LDL) 
 High density lipoprotein ( HDL)  
 Total cholesterol  
 Samples were estimated on a fully automated chemistry analyzer 
[Hitachi-912] by using standard commercially available kits or a 
standard methodology was adopted wherever necessary (Pic B). 
 
Pic B: Fully automated chemistry analyzer [Hitachi-912] at 
department of biochemistry, SKIMS. 
 The OGTT was performed after 8 hour overnight fasting with 75 grams 
of oral anhydrous glucose load dissolved in 300ml of water. Blood 
samples for glucose and insulin were collected at 0-minutes, 60-
minutes and 120-minutes after the glucose load. Glucose was 
estimated on a fully automated chemistry analyzer [Hitachi-912] by 
using standard commercially available kits or a standard methodology 
was adopted wherever necessary. The serum insulin was estimated by 
Electrochemilumniscence (ECLIA) using Cobas e 411 (Roche 
diagnostics). 
Hormonal analysis was estimated by RIA/ IRMA in the department of 
Clinical immunology and Molecular Medicine SKIMS. The hormone 
estimation included:   
 17-OHP – to rule out non classical Congenital adrenal hyperplasia 
  T4  –  to rule out hypothyroidism 
 TSH – to rule out hypothyroidism 
 PRL- to rule out prolactinoma 
  LH 
 FSH 
 Cortisol -to rule out Cushing’s syndrome 
 Testosterone- to diagnose hyperandrogenism and to rule out 
androgen secreting ovarian or adrenal tumours. 
The sampling was arranged in such a way so that the   LH, FSH, 17-OHP 
and testosterone  was collected on 3rd to 7th day of the follicular phase 
of either spontaneous or progesterone induced menstrual cycle. 
Hormonal assays was done by (RIA) radio immunoassay (T4, 
testosterone, 17-OHP, and cortisol) and immuno-radiometric assays 
(IRMA)( TSH, LH, PRL, and FSH) using commercial kits in duplicate and 
according to supplier protocol (Pic C). 
 
 
Pic C: Gamma counter for RIA at department of immunology SKIMS 
  The aliquots for procoagulant markers and proinflammatory 
markers in the plasma were separated from basal samples. 
Procoagulant markers (PAI-1) and proinflammatory markers (s-
ICAM-1, TNF-α, MCP-1) in the plasma were assayed using ELISA 
(212,213) kits according to the respective protocols. 
 ELISA Assay: The assay used was quantitative sandwich ELISA. 
The micro titer plate is provided in the kit which is pre-coated 
with a monoclonal antibody specific to the procoagulant or 
proinflammatory marker. Standards or samples are then added 
to the appropriate micro titer plate wells with a biotin-
conjugated polyclonal antibody preparation specific for the 
marker and incubated. Marker if present, will bind and become 
immobilized by the antibody pre-coated on the wells and then 
be “sandwiched” by biotin conjugate. The micro titer plate wells 
are thoroughly washed to remove unbound marker and other 
components of the sample. In order to quantify the amount of 
marker present in the sample, Avidin conjugated to Horseradish 
Peroxidase (HRP) is added to each microplate well and 
incubated. Avidin is a tetramer containing four identical 
subunits that each has a high affinity-binding site for biotin. The 
wells are thoroughly washed to remove all unbound HRP-
conjugated Avidin and a TMB (3, 3’5, 5’ tetramethyl-benzidine) 
substrate solution is added to each well. The enzyme (HRP) and 
substrate are allowed to react over a short incubation period. 
Only those wells that contain marker, biotin-conjugated 
antibody, and enzyme-conjugated Avidin will exhibit a change in 
colour. The enzyme-substrate reaction is terminated by the 
 addition of a sulphuric acid solution and the colour change is 
measured spectrophotometrically at a wavelength of 450 nm ± 
2 nm 
(Pic  D and Pic E). 
 
 
 
 
 
 
Pic D: Microplate ELISA: coloured wells indicate reactivity. The darker 
the colour, the higher the reactivity.    
 
Pic E: ELISA Reader at department of immunology, SKIMS 
 
  Factor VIII in plasma was estimated using Coagulometric method as per 
given protocol  
 Coagulometric Assay: Plasma deficient in factor VIII, comprising the 
intrinsic pathway results in a prolonged partial thromboplastin time 
(APTT).Coagulation factor deficient plasma is used to confirm the factor 
VIII deficiency, in general and to identify and quantify coagulation 
factor deficiency in patient plasma. A mixture of the factor VIII deficient 
plasma and a patient plasma is tested in APTT assay and the result is 
interpreted using the references curve obtained with the dilution of 
standard human plasma or a normal plasma pool mixed with deficient 
plasma .A patient plasma deficient in specific factor is not able to 
compensate for the absence of factor in the corresponding coagulation 
factor deficient plasma and therefore results in  prolonged APTT (Pic F) 
 
PIC F:  showing automated coagulation analyzer in department of 
hematology, SKIMS 
 4.14 Equipments: 
 
EQUIPMENTS SOURCE 
Centrifuge AICIL 
Coagulation Analyzer SYSMEX CA 550 
Deep freezer  (-70 cᵒ) REVCO 
ELISA Reader BIO-RAD 
Gamma counter STRATEC 
Incubator AICIL 
Refrigerator Kelvinator 
Vortex mixer REMI 
 
4.15 Glass and plastic ware used:  
 
Glass  And Plastic Ware SOURCE 
Appendrof tubes Tarson 
Beakers Borosil 
Clot activator vial  AcCuvet-plus 
Glass pipettes Borosil 
Measuring tubes Borosil 
Micro tips Tarson 
Test tube stand  Prolab 
Tip boxes Axygen 
Tri sodium citrate vials AcCuvet-plus 
 
 
 
 
 
 4.16 Kits: 
Kits  Method  Source 
 Cholesterol CHOD-PAP DIALAB; Austria 
Cortisol             RIA DIASORIN ;North western Ave 
Factor VIII Coagulometric method SIEMENS ;USA 
FSH                   IRMA  DPC;USA 
Glucose           GOD-POD URILAB; India 
HDL   New clearance method RANDOX;UK 
LDL   New clearance method RANDOX;UK 
LH IRMA DPC;USA 
MCP- 1            ELISA  PUREGENE; Minneapolis, USA 
PAI-1                 ELISA  SYMANSIS; New zealand 
PRL                  IRMA  DPC;USA 
s-ICAM              ELISA  GEN-PROBE;US 
T4   RIA  DIASORIN; North western Ave 
Testosterone RIA IMMUNOTECH ;France 
TG GPO-PAP  DIALAB; Austria 
TNF-α ELISA  INVITROGEN; California 
TSH IRMA IMMUNOTECH ;France 
17-OHP RIA IMMUNOTECH ;France 
 
  
  
 
  
  
 
Chapter 5 
RESULTS 
 A total of 81 subjects with PCOS participated in the study. 30 subjects who 
received OCP’s were taken as cases and were compared with 51 subjects with 
PCOS who received no treatment (drug naive) and were considered as 
controls. All subjects met the Rotterdam 2003 criteria for a positive diagnosis 
of PCOS.    
5.1 CLINICAL PARAMETERS 
The mean age of controls and cases was (21.92±5.83 vs. 21.63±4.18 years) 
respectively and was comparable (p=0.813) as shown in Fig 1 & Table 1.  
Among the controls, 17 (33.3%) subjects were in the age group of 13-18 
years, 20 (39.2%) were in the age-group of 19-24years, 14 (27.4%) subjects 
were in the age group of 25-30 years. Among cases 8 subjects (26.6%) were in 
the age-group of 13-18 years, 12 subjects (40%) were in the age group of 19-
24 years and 10 subjects (33.3%) were in age group 25-30 years.  
 
 
 
Fig 1. Showing comparison of mean age in years between cases vs. controls 
in years 
The mean age at menarche for controls and cases was (12.96±1.49 vs. 
13.13±1.27 years) respectively and was comparable (p=0.597) shown in Fig 2 
 & Table 1. Among  the controls 6 subjects had  (11.7%)    menarche  at  11 
years of  age,16 subjects (31.3%)  had   menarche at 12 years of age,14 
subjects ( 27.4%)   at 13 years of age,  8 subjects  (15.6%)   at 14 years of age, 
5 (9.8%) subjects  at 15 years of age, and  2 (3.9%) subjects had  menarche at 
16 years of age. Similarly among   cases 2 subjects (6.6%) had age of 
menarche at 11years of age, 6 subjects (20%) had age of menarche at 12 years 
of age, 14 subjects (46.6%) had at 13 years, 5 subjects (16.6%) had at 14 
years, and 3(10%) had age of menarche at 15 years of age.  
 
 
 
Fig 2.Showing comparison of mean age of menarche in years  between 
cases and controls in years. 
 
 
 
 
 Table 1. Showing comparison of mean age and age of menarche between 
cases and controls. 
 
Parameters Drug naive group 
(Controls) 
 (Mean±SD)           
N=51 
OCP group  (Cases) 
(Mean±SD)    
  N=30 
p-value 
Mean Age 
(years) 
21.92±5.83 21.63±4.18 0.813 
Age of 
menarche(years)  
12.96±1.49 13.13±1.27 0.597 
 
 
Mean number of menstrual cycles per year for controls and cases was 
(9.12±3.88 vs.9.90±3.30) respectively and was comparable (p=0.358) shown 
in Fig 3. & Table 2. Among controls 19 (37.2%) subjects had < 8 cycles per 
year, 25 (49%) subjects had 8-12 cycles per year and 7 (13.7%) subjects had 
greater than 12 cycles per year. Among cases 5 subjects (16.6%) had < 8 
cycles per year while 25 subjects (83.8%) had 8 -12 cycles per year and none 
of the subjects had greater than 12 cycles per year.  
 
 
 
  
 
Fig 3. Showing comparison of number of cycles per year between cases and 
controls.   
 
Mean Ferriman-Gallwey (FG score) of the controls and cases was (12.27±4.71 
vs. 10.00±2.60) respectively and was statistically significant (p=0.017) shown 
in Fig 4 & Table 2. The FG score of >8 was seen in 10 (33.3%) cases and 15 
(29.4%) controls while as a score of >10 was seen in 15 (50%) cases and 34 
(66.6%) controls.  
 
 
 
  
 
Fig 4. Showing comparison of mean Ferrimen-Gallwey score (FG score)  
between cases and controls. 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. Showing comparison of mean number of menstrual cycles per year 
and FG score between cases and controls. 
 
 
Parameters Drug naive group 
(Controls) 
(Mean±SD)        N=51 
OCP 
group(Cases) 
(Mean±SD) N=30 
p-value 
No of cycles per 
year 
9.12±3.88 9.90±3.30 0.358 
Ferriman-
Gallwey score  
(FG-score) 
12.27±4.71 10.00±2.60 0.017 
 
 
 
 
 
 
 
 
 
 
 
 
 5.2 ANTHROPOMETRIC PARAMETERS 
Mean weight  of controls and cases was (58.57±8.52  vs  59.07±6.34 kg)  
which was comparable (p=0.782) shown in Fig 5 & Table 3. 
 
 
 
 
 
Fig 5. Showing comparison of body weight in kg between cases and 
controls. 
 
 
 
 
 
 
 
 
 
 Mean Body mass index (BMI) of controls and cases was (23.66±3.43 vs. 
24.07± 3.42 Kg/m²) and was comparable (p=0.606) as shown in Fig 6 &Table 
3. As per International Diabetes Federation (IDF), among  controls  33 
subjects  (64.7%)   had BMI less than  25 kg/m
2 
(optimal weight),14  (27.4%)  
had  BMI between 25-30 kg/m
2 
(over weight), 4 (7.8%) were having BMI 
greater than 30 kg/m
2
 (obese).Among the cases 19 subjects (63.3%)   had BMI  
less than  25 (optimal weight),  9 (30%)  had BMI between 25-30 Kg/m
2 
(overweight) and 2 subjects  (6.6%)  had BMI greater than  30 Kg/m
2 
(obese). 
 
 
 
Fig 6. Shows comparison of mean BMI  in kg/m
2
 between cases and 
controls. 
 
 
 
 
 Mean waist circumference of controls and cases was (79.96±10.15 vs. 
78.20±8.49 cm)    respectively which was comparable (p=0.427) as shown in 
Fig 7 &Table 3.  As per National Cholesterol Education Programme Adult 
Treatment Panel III (NCEP ATP III) 2001 criteria waist circumference of 
greater than 88 cm represents central obesity. Among   controls 13 subjects 
(25.4%) had waist circumference greater than 88 cm, 38 (74.50%) have waist 
circumference less than 88 cm. Among cases 4 females   (13.33%) had waist 
circumference greater than 88 cm and 26 (86.6%) had waist circumference 
less than 88 cm. 
As per European Group for Study of Insulin Resistance (EGIR) 1999 criteria 
waist circumference of greater than 80 cm represents central obesity. Among   
controls 25 subjects (49.0%) had waist circumference greater than 80 cm, 26 
subjects 50.9% had waist circumference less than 80 cm. Among   cases 11 
subjects   (36.6%) had waist circumference greater than 80 cm and 19 subjects 
(63.33%) had waist circumference less than 80 cm. 
 
 
 
Fig 7.Showing comparison of   mean waist circumference in  cm between 
cases and controls. 
 Mean waist hip ratio for controls and cases was (0.91±0.06 vs.  0.92±0.06) 
respectively which was comparable (p=0.544) and is shown in Fig 8 &Table 
3. Waist hip ratio of greater than 0.85 is central obesity. Among   controls 44 
(86.2%) subjects have Waist hip ratio greater than 0.85 and 7 subjects (13.7%) 
had waist hip ratio less than 0.85. Among 30 cases 27 (90%) subjects had 
waist hip ratio of greater than 0.85 and 3 subjects (10%) had waist hip ratio 
less than 0.85. 
 
 
 
 
Fig 8. Showing comparison of mean waist hip ratio between cases and 
controls. 
 
 
 
 
 
 
 5.3 HEMODYNAMIC PARAMETERS 
Mean of systolic blood pressure in controls and cases  was (122.24±6.99 vs 
123.00±7.21 mm of Hg)  which was comparable (p=0.640) shown in Fig 9 
&Table 3.As per International Diabetes Federation (IDF) systolic blood 
pressure of  greater than 130 mm  Hg is diagnosed as  systolic hypertension. 
Among controls 11(21.5%) subjects have systolic blood pressure greater than 
130 mm  Hg  and 40 (78.4%) subjects have systolic blood pressure within the 
normal range. Among cases 9 (30%) subjects have systolic blood pressure  
greater than 130 mm  Hg and 21 (70%) subjects have systolic blood pressure 
within the normal range. 
 
 
 
Fig 9. Showing comparison of mean systolic BP  in mm  Hg between cases 
and controls. 
 
 
 
 Mean  diastolic blood pressure  in controls and cases was (79.37±4.62 vs 
79.46±4.29 mm of Hg ) which was comparable (p=0.928) shown if Fig 10 
&Table 3.As per International Diabetes Federation (IDF) diastolic blood 
pressure of  85 mm  Hg is diagnosed as diastolic hypertension.. 
Among controls 8 (15.6%) women have diastolic blood pressure greater than 
85 mm of Hg,43 subjects (84.3%) have diastolic blood pressure within the 
normal range. Among cases  4 (13.3%) women have diastolic blood pressure  
greater than 85mm  Hg and 26(86.6%) diastolic blood pressure within the 
normal range.   
 
 
 
 
Fig 10.Showing comparison of mean diastolic BP  in mm  Hg between cases 
and controls. 
 
 
 
 
 Table 3. Showing comparison of anthropometric variables and  hemodynamic 
parameters (BP) between cases and controls. 
 
 
Parameters Drug naive group 
(Controls) 
(Mean±SD)        N=51 
OCP group (Cases) 
(Mean±SD) N=30 
p-value 
Weight(kg) 58.57±8.52 59.07±6.34 0.782 
Waist(cm) 79.96±10.15 78.20±8.49 0.427 
Waist-Hip ratio (WHR) 0.91±0.06 0.92±0.06 0.544 
BMI (Kg/m
2
) 23.66±3.43 24.07±3.42 0.606 
Systolic BP (mm of Hg) 122.24±6.99 123.00±7.21 0.640 
Diastolic BP(mm of Hg) 79.37±4.62 79.46±4.29 0.928 
 
 
 
 
 
 
 
 
 
 
 
 
 5.4 BIOCHEMICAL PARAMETERS 
Mean   fasting   blood glucose in control and cases who participated in our 
study was (87.75±19.9 vs. 88.77±10.41 mg/dl) respectively which was 
comparable (p=0.795) as shown in Fig 11 & Table 4. As per Modified US 
National Cholesterol Education Programme Adult Treatment Panel III (NCEP 
ATP III) criteria, fasting glucose equal to or greater than 100 mg/dl is 
diagnosed as impaired fasting glucose. Among controls 6 (11.7%) subjects 
had fasting glucose equal to or greater than 100 mg/dl (impaired fasting 
glucose). Among cases 3 (10%) subjects have fasting glucose equal to or 
greater than 100 mg/dl (impaired fasting glucose).  
 
 
 
Fig 11. Showing comparison of fasting blood glucose in mg/dl between 
cases and controls. 
 
 
 
 Mean blood glucose 2 hr in controls and cases was (109.27±43.9 
vs.108.77±25.70 mg/dl) respectively which was comparable (p=0.954) as 
shown in Fig 12 & Table 4.  Among controls 3 subjects (5.8%) have 2 hr 
glucose between140-199 mg/dl that is impaired glucose tolerance as per 
World Health Organization (WHO) criteria while as  48 females (94.11%) had 
2 hr glucose  within normal range. Among cases 4 (13.3%) subjects had 2 hr 
glucose between 140-199 mg/dl and 26   subjects (86.6 %) had 2 hr glucose 
within normal range. 
 
 
Fig 12. Showing comparison of blood glucose 2 hr in mg/dl between cases 
and controls. 
 
 
 
 
 
 
 
 As per WHO criteria fasting glucose equal to or greater than 126 mg/dl and/or 
glucose 2 hr equal to or greater than 200 mg/dl is diagnosed as diabetes 
mellitus. Among controls 2 subjects (3.92%) have fasting glucose greater than 
126 mg/dl and 1 subject (1.9%) had 2hr glucose greater than 200 mg/dl.   
Mean serum cholesterol level among controls and cases was (155.07 ±28.86   
vs. 186.10±44.76 mg/dl) respectively which was statistically significant 
(p=0.000) shown in Fig 13 & Table 4.  As per International Diabetes 
Federation (IDF) 2006, serum cholesterol greater than 200mg/dl is diagnosed 
as dyslipidemia. Among controls 7 subjects (13.72%) have cholesterol greater 
than 200 mg/dl, 44 females (86.2%) have cholesterol in the normal range. 
Among   cases 9 subjects (30%) have cholesterol greater than 200 mg/dl and 
21 subjects (70%) have cholesterol within normal range. 
Mean   serum   triglyceride levels   in controls and cases was 113.00±46.47   
vs. 118.17±41.14 mg/dl) respectively which was comparable (p=0.616) shown 
in Fig 13  &Table 4. As per International Diabetes Federation (IDF) 2006 
serum triglycerides greater than 150 mg/dl is diagnosed as dyslipidemia. 
Among controls 7 subjects (13.72%) have triglycerides greater than 150 
mg/dl, 44 subjects (86.2%) have triglycerides in normal range. Among cases 5 
subjects (16.6%) have triglyceride greater than 150 mg/dl and 25 subjects 
(83.33 %) have   triglyceride   within normal range. 
Mean HDL cholesterol in controls and cases was (45.35±9.99 vs. 48.90±11.90 
mg/dl) which was comparable (p=0.155) shown in Fig 13 & Table 4. As per 
International Diabetes Federation (IDF) 2006, HDL cholesterol less than 
50mg/dl is diagnosed as dyslipidemia. Among   controls 42 subjects (82.35%) 
have HDL less than 50mg/dl, 9 subjects (17.64%) have in normal range. 
Among   cases 21 subjects (70%) have HDL less than 50 mg/dl and 9 (30 %) 
have HDL within normal range. 
Mean LDL value in controls and cases was (83.20±27.6 vs. 118.45±45.66 
mg/dl) respectively which was statistically significant (p=0.000) shown in Fig 
 13 & Table 4.  As per International Diabetes Federation (IDF) 2006, LDL 
cholesterol greater than 100 mg/dl diagnosed as dyslipidemia. Among controls 
11 subjects (21.5%) have LDL greater than 100mg/dl, 40 subjects (78.43%)   
have LDL in normal range. Among   cases 18 (60%) have LDL greater than 
100 mg/dl   and 12 subjects (40 %) have LDL within normal range.  
 
 
 
 
Fig 13. Showing comparison of lipid profile in mg/dl between cases and 
controls. 
 
 
 
 
 Table 4.Showing comparative description of OGTT derived blood glucose 
values and lipidogram of cases and controls. 
 
Parameters Drug naive group (Controls) 
(Mean±SD) N=51 
OCP group  (Cases) 
(Mean±SD) N=30 
p-value 
Blood glucose- Fasting 
(mg/dl) 
87.75±19.91 88.77±10.41 0.795 
Blood glucose-1 hour 122.06±45.46 124.60±28.93 0.784 
Blood glucose- 
2hour(mg/dl) 
109.27±43.95 108.77±25.70 0.954 
Serum Total cholesterol 
(mg/dl) 
155.08±28.86 186.10±44.76 0.000 
Serum Triglycerides 
(mg/dl) 
113.00±46.47 118.17±41.14 0.616 
Serum HDL(mg/dl) 45.35±9.99 48.90±11.90 0.155 
Serum LDL(mg/dl) 83.20±27.63 118.45±45.66 0.000 
 
 
 
 
 
 
 
 
 
 
 
 
 5.5 INSULIN SENSITIVITY PARAMETERS 
Mean fasting insulin levels in controls and cases were (12.28±11.10 vs. 
16.23±24.72 µIU/ml) which were comparable (p=0.326) shown in Fig 14  & 
Table 5. Among controls 27 females (52.94%) have fasting insulin greater 
than 10 µIU/ml   and 24 females (47.05%) have fasting insulin within the 
normal range. Among cases 14 subjects (46.6%) have insulin greater than 10 
µIU/ml and 16 subjects (53.3%) have insulin within the normal range. 
Insulin one hour in controls and cases was found to be (65.89 ± 43.97 vs. 
59.42 ±34.76 µIU/ml) respectively which was comparable (p=0.493) shown in 
Fig 14  &Table 5. 
Insulin two hour in controls and cases was (43.43±36.07 vs. 65.69±63.67 
µIU/ml) respectively which was comparable (p=0.48) shown in Fig 14 &Table 
5. 
 
 
Fig 14.Showing comparison of fasting, 1 hour, 2 hour insulin levels in 
µIU/ml between cases and controls 
FGIR (Fasting glucose to insulin ratio) in controls and cases  was found to be 
(10.03±5.34 and 11.60±9.3) respectively which was comparable (p=0.336) 
shown in Fig 15  & Table 5.  
 
  
 
Fig 15.Showing comparison of mean FGIR between  cases and controls. 
 
HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) in controls 
and cases was found to be 2.73±2.64 vs. 3.00±4.17   which was comparable 
(p=0.335) shown in Fig 16 &Table 5.   
 
 
Fig 16.Showing comparison of  HOMA-IR between cases and controls. 
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 QUICKI (Quantitative Insulin Sensitivity Check Index) in controls and cases 
was found to be (0.516±0.01 vs. 0.513±0.013) respectively which was 
comparable (p=0.449) shown in Fig 17 & Table  5. 
 
 
 
 
 
Fig 17. Showing comparison of QUICKI between cases and controls. 
 
 
 
 
 
 
 
 Table 5. Showing comparison of OGTT derived insulin sensitivity parameters 
among cases and controls 
 
 
Parameters Drug naive group  
(Mean±SD) 
 N=51 
OCPgroup  
(Mean±SD) 
 N=30 
p value 
Serum insulin- Fasting (µIU/ml) 12.28±11.10 16.23±24.72 0.326 
Serum insulin -1hour (µIU/ml) 65.89±43.97 59.42±34.76 0.493 
Serum insulin-2hour(µIU/ml) 43.43±36.07 65.69±63.67 0.48 
FGIR 10.03±5.34 11.60±9.30 0.336 
HOMA-IR 2.73±2.64 3.00±4.17 0.335 
QUICKI 0.516±0.01 0.513±0.013 0.449 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.6 HORMONAL PARAMETERS 
Mean luteinizing hormone (LH) value of controls and cases was found to be 
(8.17±6.14 vs. 6.75±6.26 IU/L) respectively which is comparable (p=0.322) 
shown in Fig 18 &Table 6. Among controls 10 females (19.6%) have LH/FSH 
ratio greater than 2, while 41 subjects (80.3%)   have normal LH/FSH ratio. 
Among cases 7 subjects (23.3%) have LH/FSH ratio greater than 2 while 23 
subjects (76.6%) have normal LH/FSH ratio. 
 
 
 
Fig 18.Showing comparison of mean LH values in IU/L between cases and 
controls. 
 
 
 
  Mean FSH value in the two groups of controls and cases was found to be 
(6.17±2.21 vs. 4.88±2.17 IU/L) which is statistically significant (p=0.013) 
shown in Fig 19 & Table 6.  
 
 
 
Fig 19. Showing comparison of mean FSH levels in IU/L between cases and 
controls. 
 
 
 
 
 
 
 
 
 Mean   testosterone levels of controls and cases was found to be (63.31±31.30 
vs. 56.05±31.81 ng/dl) respectively which was comparable (p=0.320) shown 
in Fig 20 & Table 6.Among controls 26 subjects (50.9%) had testosterone >65 
ng/dl, while 25 subjects (49%) have testosterone within normal range. Among 
cases 7 subjects (23.3%) have testosterone >65 ng/dl while 23 subjects 
(76.6%) have testosterone within normal range.  
 
 
 
Fig 20. Showing comparison  mean total serum testosterone levels in ng/dl  
between cases and controls. 
 
 
 
 Table 6 . Showing comparative description of mean serum gonadotrophins 
and the mean total serum testosterone levels in ng/dl  between cases and 
controls . 
 
Parameters 
Drug naive  group 
(Mean± SD) 
N=51 
OCP group 
(Mean± SD) 
N=30 
P value 
Serum LH (IU/L) 8.17±6.14 6.75±6.26 0.322 
FSH  (IU/L) 6.17±2.21 4.88±2.17 0.013 
Serum total 
testosterone (ng/dl) 
63.31±31.30 56.05±31.81 0.320 
 
 
 
 
 
 
 
 
 
 
 5.7 PROCOAGULANT AND PROINFLAMMATORY MARKERS 
Mean plasma soluble intercellular adhesion molecule-1 (s-ICAM-1) values in 
controls and cases were found to be (312.41±131.65 vs. 417.03±131.65 ng/ml) 
respectively and was statistically significant (p=0.001) shown in Fig 21 & 
Table 7. 
 
 
 
 
Fig 21. Showing comparison of soluble ICAM-1 in ng/ml values between 
cases and controls 
 
 
 
  Mean Monocyte chemo attractant protein-1 (MCP-1) value in controls and 
cases was found to be (456.78±187.2 vs. 464.82 ± 91.19 pg/ml)  which was 
comparable (p=0.827) shown if Fig 22 & Table 7.  
 
 
 
 
Fig 22.Showing comparison of MCP-1 pg/ml between  cases and controls. 
 
 
 
 
 Mean TNF-α levels in controls and cases was found to be 22.85±5.19 vs. 
25.60±4.24 which is statistically significant   (p=0.016) shown in Fig 23 and 
Table 7.  
 
 
 
Fig 23. Showing comparison of TNF-α level  in pg/ml between cases and 
controls. 
 
 
 
 
 
 
 Mean PAI-1 levels in controls and cases was found to be (1.05±0.40 vs. 
1.10±0.59 ng/ml) which is comparable (p=0.682) shown in Fig 24  & Table 7.  
 
 
 
 
Fig 24. Showing comparison of PAI -1 levels in ng/ml between cases and 
controls 
 
 
 
 
 
 Mean factor VIII levels in controls and cases  was found to be 0.685±0.32 and 
0.350±0.33   which is statistically significant (p=0.00) shown in Fig 25 & 
Table 7. 
 
 
 
Fig 25. Showing comparison of Factor VIII levels between cases and 
controls 
 
 
 
 
 
 Table 7. Showing comparison of s-ICAM-1, MCP-1,TNF-alpha, Factor  
VIII  and serum PAI-1 levels between cases and controls 
Parameters Drug naive group 
(Mean±SD) N=51 
OCP group 
 (Mean±SD) N=30 
p-value 
s-ICAM-1 (ng/ml) 312.41±131.65 417.03±131.62 0.001 
MCP-1(pg/ml) 456.78±187.25 464.82±91.19 0.827 
TNF-α  (pg/ml) 22.85±5.19 25.60±4.24 0.016 
FACTOR VIII  0.68±0.32 0.35±0.33 0.000 
PAI-1 (ng/ml) 1.05±0.40 1.10±0.59 0.682 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.8 CORRELATION  
In Pearson’s correlation between the procoagulant, proinflammatory markers 
and different anthropometric, biochemical & hormonal   parameters, 
statistically significant and negative correlation was found between factor VIII 
and INS 0 hr (r=-0.234, p=0.036), HOMA-IR (r=-0.233, p=0.037) and s-
ICAM-1 (r=-0.239, p=0.032) shown in table 8-10. 
 
Table 8: Showing correlation of Factor VIII with clinical and 
anthropometric parameters. 
 
Parameters r p 
Age 0.125 0.266 
Menarche -0.055 0.625 
Cycles/year -0.053 0.637 
FG score 0.077 0.496 
Wt 0.014 0.898 
BMI kg/m
2
 0.056 0.620 
Waist (cm) 0.061 0.586 
hip (cm) -0.023 0.839 
Waist hip ratio 0.147 0.191 
SBP mm of Hg -0.162 0.149 
DBP mm of Hg -0.144 0.201 
 
 
 
 
 Table 9: Showing correlation of Factor VIII with different hormonal, 
biochemical and insulin sensitivity parameters. 
 
Parameters r p 
LH  (IU/L) -0.031 0.781 
FSH (IU/L) -0.072 0.522 
Serum total testosterone (ng/ml) 0.123 0.276 
Blood glucose fasting (mg/ml) -0.026 0.818 
Blood glucose -1 hr(mg/dl) 0.085 0.450 
Blood glucose -2 hr (mg/dl) 0.062 0.580 
Plasma insulin fasting (µIU/ml) -0.234* 0.036 
Plasma insulin -1 hr (µIU/ml) 0.027 0.812 
Plasma insulin -2hr (µIU/ml) -0.197 0.078 
HOMA-IR -0.233* 0.037 
FGIR 0.044 0.696 
QUICKI 0.109 0.334 
 
 
 
 
 
 
 
 
 
 
 
 Table 10: Showing correlation of Factor VIII with different  lipid 
parameters, pro- coagulant and inflammatory markers  
 
Parameters r p 
Total cholesterol ( mg/dl) -0.199 0.076 
Triglycerides ( mg/dl) -0.092 0.416 
HDL ( mg/dl) -0.155 0.167 
LDL ( mg/dl) 0.174 0.`119 
PAI (ng/ml) 0.013 0.907 
TNF-α (pg/ml) -0.158 0.158 
MCP-1 (pg/ml) -0.033 0.767 
s-ICAM-1 (ng/ml) -0.239* 0.032 
 
 
 
 
 
 
 
 
 
 
 
 PAI-1 showed statistically significant and positive correlation with blood 
glucose one hour (r=0.233, p=0.036)(fig 26), blood glucose two hour 
(r=0.258,p=0.020)(fig 27),Insulin two hour (r=0.309,p=0.005) and triglyceride 
level (r=0.334,p=0.002)(fig 28). PAI-1 showed negative and statistically 
significant correlation with age of menarche (r=-0.295,p=0.007) shown in 
table 11-13. 
Table 11: Correlation of Plasminogen Activator Inhibitor-1 (PAI-1)  with 
different clinical and anthropometric parameters. 
 
Parameters r p 
Age 0.064 0.571 
Menarche -0.295** 0.007 
Cycles/year -0.071 0.529 
FG score -0.127 0.257 
Wt (kg) 0.063 0.574 
BMI (kg/m
2
) 0.142 0.205 
Waist (cm) 0.203 0.070 
Waist hip ratio 0.142 0.206 
SBP   (mm  Hg) -0.117 0.299 
DBP  (mm  Hg) -0.159 0.157 
 
 
 
 
 
 
 Table 12: Correlation of Plasminogen Activator Inhibitor-1  (PAI-1) with 
different hormonal, biochemical and insulin sensitivity parameters. 
 
Parameters r P 
LH  (IU/L) 0.098 0.382 
FSH (IU/L) 0.085 0.448 
Serum total testosterone (ng/ml) 0.036 0.751 
Blood glucose fasting (mg/ml) 0.194 0.082 
Blood glucose -1 hr(mg/dl) 0.233* 0.036 
Blood glucose -2 hr (mg/dl) 0.258* 0.020 
Plasma insulin fasting (µIU/ml) 0.085 0.453 
Plasma insulin -1 hr (µIU/ml) 0.117 0.300 
Plasma insulin -2hr (µIU/ml) 0.309** 0.005 
HOMA-IR 0.115 0.307 
FGIR -8.020 0.862 
QUICKI -0.181 0.105 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig 26. Graph showing correlation between PAI-1 and blood glucose 1hr 
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Fig 27. Graph showing correlation between PAI-1 and blood glucose 2 hr 
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 Table 13: Correlation of Plasminogen Activator Inhibitor-1 (PAI-1) with 
different lipid parameters procoagulant and  inflammatory markers. 
 
Parameters r p 
Total cholesterol  ( mg/dl) 0.056 0.621 
Serum Triglycerides ( 
mg/dl) 
0.334** 0.002 
HDL ( mg/dl) -0.138 0.220 
LDL ( mg/dl) 0.099 0.379 
Factor  VIII 0.013 0.907 
TNF-α (pg/ml) -0.143 0.202 
MCP-1 (pg/ml) 0.126 0.261 
s-ICAM-1 (ng/ml) 0.090 0.422 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig 28.Graph showing correlation between PAI-1 and Triglyceride 
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 TNF-α showed statistically significant but negative correlation with FSH 
levels (r=-0.255, p=0.022), Insulin one hour (r=-0.308, p=0.005)(fig 29) but 
statistically significant and positive correlation with sICAM-1 (r=0.292, 
p=0.008) shown in table 14-16. 
 
Table 14:  Correlation of plasma Tumor Necrosis Factor-α (TNF-α) levels 
with different clinical and anthropometric   parameters 
 
Parameters r p 
Age -0.040 0.722 
Menarche 0.142 0.206 
Cycles/year -0.064 0.571 
FG score -0.105 0.350 
Wt kg -0.035 0.756 
BMI kg/m
2
 -0.005 0.962 
Waist (cm) -0.077 0.497 
Waist hip ratio 0.030 0.791 
SBP mm of Hg -0.40 0.726 
DBP mm of Hg -0.093 0.411 
 
 
 
 
 Table 15: Correlation of plasma Tumor Necrosis Factor-α (TNF-α) levels 
with different hormonal, biochemical and insulin sensitivity parameters. 
 
Parameters r p 
LH  (IU/L) -0.135 0.229 
FSH (IU/L) -0.255* 0.022 
Serum total testosterone (ng/ml) 0.012 0.914 
Blood glucose fasting (mg/ml) -0.038 0.739 
Blood glucose -1 hr(mg/dl) 0.093 0.408 
Blood glucose -2 hr (mg/dl) -0.049 0.665 
Plasma insulin fasting (µIU/ml) 0.076 0.501 
Plasma insulin -1 hr (µIU/ml) -0.308** 0.005 
Plasma insulin -2hr (µIU/ml) -0.162 0.149 
HOMA-IR 0.059 0.603 
FGIR 0.069 0.542 
QUICKI 0.054 0.631 
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Fig 29.Graph showing correlation between  and TNF-α and insulin 1hr 
 
 
 
 
 
 
 
 Table 16: Correlation of plasma Tumor Necrosis Factor-α (TNF-α)  levels 
with different  lipid parameters,  procoagulant and inflammatory 
markers. 
 
Parameters r p 
CHOL ( mg/dl) 0.120 0.286 
TG ( mg/dl) 0.172 0.124 
HDL ( mg/dl) 0.082 0.466 
LDL ( mg/dl) 0.078 0.488 
Factor VIII  -0.158 0.158 
TNF-α (pg/ml) -0.143 0.202 
MCP-1(pg/ml) 0.111 0.322 
s-ICAM-1 (ng/ml) 0.292** 0.008 
 
 
 
 
 
 
 
 MCP-1 showed statistically significant and positive correlation with   fasting 
blood glucose levels (r=0.296, p=0.007)(Fig 30).statistically significant but 
inverse correlation with QUICKI (r=-0.274, p=0.013) (Fig 31)shown in table 
17-19. 
Table 17: Correlation of Monocyte chemo attractant protein-1 (MCP-1) 
with different clinical and anthropometric parameters 
 
Parameters r p 
Age -0.115 0.306 
Menarche 0.051 0.651 
Cycles/year -0.138 0.218 
FG score 0.013 0.909 
Wt -0.014 0.903 
BMI kg/m
2 
0.098 0.384 
Waist (cm) -0.009 0.934 
hip (cm) 0.040 0.725 
Waist hip ratio -0.069 0.5420 
SBP mm of Hg -0.124 0.268 
DBP mm of Hg -0.067 0.553 
 
 
 
 
 
 
 Table 18: Correlation of plasma Monocyte   chemoattractant protein-1 
(MCP-1)  levels with different  hormonal ,biochemical  and insulin 
sensitivity parameters. 
 
Parameters r p 
LH  (IU/L) 0.161 0.151 
FSH (IU/L) 0.101 0.371 
TESTO (ng/ml) 0.019 0.866 
BG OA(ng/ml) 0.296** 0.007 
BG IA (mg/dl) 0.184 0.101 
BG 2A(mg/dl) 0.127 0.257 
IN OA (µIU/ml) 0.016 0.886 
IN IH (µIU/ml) 0.074 0.509 
IN 2H (µIU/ml) -0.030 0.791 
HOMA-IR 0.052 0.642 
FGIR 0.035 0.759 
QUICKI -0.274* 0.013 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig 30  Graph showing correlation between MCP-1 and fasting  blood 
glucose   
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            Fig 31.  Graph showing correlation between MCP-1 and QUICKI 
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 Table19: Correlation of plasma Monocyte chemoattractant protein-1 
(MCP-1) levels with different  lipid parameters, procoagulant and 
inflammatory markers. 
 
 
Parameter r p 
CHOL ( mg/dl) -0.031 0.782 
TG ( mg/dl) 0.064 0.569 
HDL ( mg/dl) 0.018 0.875 
LDL ( mg/dl) -0.059 0.601 
Factor VIII -0.033 0.767 
PAI (ng/ml) 0.126 0.261 
TNF-α (pg/ml) 0.111 0.322 
s-ICAM-1 (ng/ml) 0.103 0.362 
 
 
 
 
 
 
 
 
 s-ICAM-1 showed statistically significant but positive correlation with fasting 
blood glucose (r=0.427,p=0.000) blood glucose one hour (r=0.350,p=0.001), 
blood glucose two hour (r=0.287,p=0.009),fasting insulin levels 
(r=0.347,p=0.001)(fig 32), HOMA-IR (r=0.405,p=0.000)(fig 33), and 
triglyceride (r=0.344,p=0.002) and TNF-α (r=0.292,p=0.008).ICAM showed 
statistically significant but negative correlation with QUICKI (r=-
0.437,p=0.000) (fig 34), FACTOR VIII (r=-0.239,p=0.032) and systolic blood 
pressure (r=-0.248,p=0.026) shown in table 20-22.   
Table 20: Showing correlation of Intercellular adhesion molecule-1 
(ICAM-1) with different clinical and anthropometric parameters 
 
Parameters r p 
Age -0.055 0.626 
Menarche -0.044 0.695 
Cycles/year 0.057 0.616 
FG score -0.077 0.496 
Wt 0.060 0.593 
BMI kg/m
2
 0.063 0.579 
Waist (cm) 0.067 0.551 
hip (cm) 0.021 0.855 
Waist hip ratio 0.085 0.449 
SBP mm of Hg -0.248* 0.026 
DBP mm of Hg -0.200 0.074 
 
 
 Table 21: Correlation of plasma Intercellular adhesion molecule-1 
(ICAM-1)  levels with different hormonal, biochemical and insulin 
sensitivity parameters. 
 
Parameters  r p 
LH  (IU/L) 0.054 0.634 
FSH (IU/L) -0.037 0.744 
TESTO (ng/ml) -0.204 0.067 
BG OA(ng/ml) 0.427* 0.000 
BG 1A (mg/dl) 0.350** 0.001 
BG 2A(mg/dl) 0.287** 0.009 
IN OA (µIU/ml)  0.347** 0.001 
IN IH (µIU/ml) -0.215 0.054 
IN 2H (µIU/ml) 0.000 0.997 
HOMA-IR 0.405** 0.000 
FGIR 0.065 0.567 
QUICKI -0.437** 0.000 
 ICAM(ng/mL)
10008006004002000
IN
S
. 
 0
A
140
120
100
80
60
40
20
0
 
Fig 32. Graph showing correlation between ICAM-1 and fasting insulin 
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Fig 33. Graph showing correlation between ICAM-1 and HOMA-IR 
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        Fig 34. Graph showing correlation between sICAM-1 and QUICKI 
 
 
 
 
 
 
 
 
 
 
 Table22: Correlation of plasma Intercellular adhesion molecule-1 
(ICAM-1) levels with different lipid parameters, procoagulant and 
inflammatory markers 
 
Parameters r p 
CHOL ( mg/dl) 0.161 0.152 
TG ( mg/dl) 0.344** 0.002 
HDL ( mg/dl) -0.166 0.138 
LDL ( mg/dl) 0.217 0.052 
Factor VIII -0.239* 0.032 
PAI (ng/ml) 0.090 0.422 
TNF-α (pg/ml) o.292** 0.008 
MCP-1 (pg/ml) 0.103 0.362 
  
No statistically significant correlation was observed between markers (PAI-1 
TNF-α, MCP-1, factor VIII and s-ICAM-1) and rest of anthropometric, 
hormonal and biochemical parameters as shown in tables above. 
 
 
 
 
 
  
 
  
 
Chapter 6 
DISCUSSION   
  
COS is characterized by hyper androgenic manifestation like acne, 
hirsutism and chronic anovulation and is associated with much metabolic 
derangement such as hyperlipidemia, hyperinsulinemia, insulin resistance and 
type 2 diabetes. Inflammation has been implicated as an important etiological 
factor in the development of both insulin resistance and type 2 diabetes 
mellitus in PCOS. For most of the clinician’s first line of treatment of PCOS is 
OCP’s. Although OCP’s seem to be an efficient mode of therapy for hyper 
androgenic symptoms associated with PCOS but their possible negative 
effects on insulin metabolism, glucose metabolism, lipid metabolism, blood 
coagulation, and inflammation should be taken into consideration. To know 
this our study aimed to evaluate the proinflammatory and procoagulant 
markers in drug naive and OCP treated women with PCOS. To help us to 
answer the question of safety of using OCP’s as conventional treatment of 
PCOS and if monitoring is required to estimate the risk of CVD in PCOS 
women treated with OCP’s.  
 Our results demonstrated that treatment with OCP’s (E+P) is associated with 
significant improvement in FG score (androgenic hair growth), acne vulgaris 
and regularization of menstrual cycles. In agreement with our findings 
previous studies showed that OCP’s induce predictable cyclic menses, reduce 
luteinizing hormone secretion and lower ovarian androgen production (154); 
the estrogen component increases SHBG, thus reducing free androgens 
(Ehrmann,2005) OCP’s have been shown to reduce inflammatory acne counts 
by 30–60% with improvement in 50–90% of the subjects (James, 2005) (160). 
Besides the progestin component protects the endometrium from hyperplasia.  
The present study showed statistically insignificant, small increase 
in anthropometric parameters like weight, BMI (Kg/m
2
) and waist hip ratio in 
PCOS women in the OCP’s arm as compared to drug naive PCOS arm. Few 
studies evaluating body composition during OCP treatment, showed no 
P 
 significant change in body weight or body fat (214-216). Stachenfeld NS et al 
(1998) showed that OCP’s can lead to significant body fluid retention (217). 
Our results suggest insignificant weigh gain in OCP users which shows 
negative effect of OCP’s on body composition of PCOS women. We observed 
small elevation in systolic BP (mm Hg) in OCP treated PCOS group compared 
to drug naive patients which is in agreement with most of published studies in 
normotensive women (218). A review of 2 studies found an increase in 
systolic blood pressure by 7 to 8 mm Hg on average compared with systolic 
blood pressure in those not using OCP’s (219,220).  A study on 80 healthy 
women randomized into groups of 3 mg of drospirenone combined with a 30-, 
20-, or 15-µg dose of equine estrogen (EE) found that systolic blood pressure 
at 6 months fell by a range of 1 to 4 mm Hg across the groups, compared with 
an elevation of blood pressure of 4 mm Hg in the control group of 
Levonorgestrel (LNG)/EEs (221). One of the study showed newer progestins 
such as drospirenone produce lower blood pressure (222). One study 
conducted by Oelkers W. K. H.  et al, (1996) reported estrogen in very high 
doses, causes hypertension (223) which is in agreement with our study. 
Previous studies reported side effects of using OCP’s, such as headache, 
nausea, breast tenderness, and weight gain (224-227) which were very 
minimal in our study. 
We observed increase in total cholesterol, LDL cholesterol, and insignificant 
increase in triglyceride & HDL cholesterol levels with OCP’s when compared 
to the drug naive PCOS patients. Previous studies have shown increase in total 
cholesterol and TG following OCP treatment which is in agreement with our 
study (Hennekens CH, 1979) (228).   Ibanez and de Zegher (2004) showed 
that abnormal adipocytokines, hypertriglyceridaemia and body adiposity 
became worse in a group of adolescents and young women given a 
drospirenone pill’s (229).  IIana J. Halperin (2010) also reported OCP use is 
 significantly associated with an increase in HDL-C and TG (230) as was 
shown by Costello et al on comparing OCP with metformin  where significant 
increase in triglycerides in the OCP group occurred as compared to metformin 
in women with PCOS (231). George Mastorakos et al (2002) in a study 
reported combined oral contraceptives were associated with an increase of 
total cholesterol, LDL cholesterol, and HDL cholesterol levels and no change 
of the total cholesterol/HDL cholesterol and LDL cholesterol/HDL cholesterol 
ratios (232). All these findings suggest OCP use is associated with elevation 
of Coronary risk as indicated by elevation of total and LDL cholesterol.  
However some authors showed  that there were no detrimental effects of 
transdermal hormone replacement therapy (HRT) on lipid profile, glucose 
metabolism, CRP and urine protein levels in  post menopausal women with 
type 2 diabetes and hypertension (233).While some studies have reported 
OCP’s ameliorate the abnormal metabolic profile of women with PCOS (234). 
OGTT results showed insignificant increase in fasting plasma glucose, fasting 
insulin (µ IU/ml), insulin 2hr (µIU/ml), FGIR and HOMA-IR levels of PCOS 
patients treated with OCP’s when compared to the drug naive PCOS patients. 
Previous studies reported that OCP’s deteriorate glucose tolerance. One of the 
earliest prospective studies on the effect of OCP on carbohydrate metabolism 
in the general population was performed by Wynn and Doar (1969), they 
reported both oral and intravenous glucose tolerance area under the curve 
(AUC) deteriorated in 78 and 70% of the women respectively, and 13% 
developed chemical diabetes during OCP therapy. Significant elevations of 
plasma insulin after both oral and intravenous glucose were also observed 
which accelerate the rate of development of clinical diabetes and also of 
atherosclerosis (235). A prospective study by Rimm et al, in 1992 showed 
10% greater risk of type 2 DM in past users of OCPs albeit with high-dose 
estrogen (236). Many authors (Korytkowski et al, 1995; Morin-Papunen et al, 
2000; Cagnacci et al, 2003; Palep-Singh et al, 2004; Vrbikova et al, 2004) 
 demonstrated deterioration in carbohydrate metabolism on using OCP’s (237-
241). Development of frank diabetes in OCP users was also reported by  
Nader et al, 1997 (242). Some studies (Falsetti and Pasinetti, 1995; Armstrong 
et al., 2001; Cibula et al., 2002; Elter et al., 2002; Morin-Papunen et al., 2003) 
reported no change in carbohydrate metabolism after OCP use (243-247). 
Chasen-Taber et al, 1997 showed no significant increase in risk with low-dose 
pills (248) and Troisi et al, 2000 showed that past and present users did not 
differ from never users in glucose, insulin, C-peptide and haemoglobin A1C 
concentrations (249). Some studies (Pasquali et al, 1999; Escobar-Morreale et 
al, 2000; Cagnacci et al, 2003) have shown OCP use resulted in improvement 
in carbohydrate metabolism (250-252).  Thus, the range of studies have shown 
conflicting results with OCP use but majority of data on insulin resistance and 
glucose intolerance favours our results suggesting a negative metabolic effect 
of OCP’s. 
As expected we observed decrease in total testosterone and serum LH levels in 
PCOS patients treated with OCP’s compared to drug naive PCOS patients.  
Significant decrease in FSH   was also observed in PCOS patients treated with 
OCP’s compared to drug naive PCOS patients. In agreement with our 
observations Ehrmann DA et al (2005) showed that estrogen component 
(ethinyl  estradiol) of  OCP’s has a role in suppression  of FSH, stabilization 
of endometrium, potentiating  of progestin action, suppression of dominant 
follicle formation, increase in sex hormone binding globulin  and decrease in 
free androgen  (154). Balen A et al 2001 suggested that progestin component 
has a role in suppression of LH, inhibition of LH surge, unreceptive 
endometrium, hostile cervical mucus, decrease in ovarian androgen secretion 
and androgen blocking effect (155). Although the effect in our study was 
marginal, most of times statistically insignificant, a larger number of subjects 
could have made the results more robust. 
 The present study showed a significant increase in serum sICAM-1 levels in 
OCP treated PCOS patients compared to drug naive PCOS patients. The 
marker also showed a positive correlation with markers of metabolic 
dysfunction and insulin resistance in women with PCOS. Previous studies 
related to sICAM-1 in PCOS showed significantly higher levels of sICAM-1 
in PCOS group than in healthy group (253). Another study demonstrated that 
endothelial dysfunction coexists and is influenced by presence of increased 
serum levels of inflammation and endothelial activation markers (ET-1, s-
ICAM, s-VCAM, hs-CRP) in young women with PCOS (254). Although OCP 
group had higher concentration than non-OCP users, we didn’t have a healthy 
control group to compare the results.  Nasiek M et al (2004) showed higher 
concentrations of sICAM-1 in women with PCOS suggesting a higher risk for 
cardiovascular diseases in this group (255) the levels have been shown to 
correspond to higher BMI, waist hip ratio and serum testosterone levels as in 
our study (256).  Gonzalez F  et al  (2009) demonstrated higher  IL-6, sICAM-
1, CRP, PAI-1, systolic and diastolic blood pressures, triglycerides, fasting 
insulin, and HOMA in women with PCOS compared with weight-matched 
controls, and the highest levels in the obese regardless of PCOS status (257). 
In our study we demonstrated that ICAM-1 levels were significantly higher in 
subjects with increased waist circumference indicating role of visceral obesity 
in chronic low grade inflammation in insulin resistance states like PCOS and 
metabolic syndrome. Our Study also revealed highly significant correlation 
between ICAM-1 and fasting plasma glucose, post glucose load  plasma 
glucose  and novel markers of insulin resistance  (HOMA-IR) again pointing 
towards role of endothelial dysfunction in insulin resistance both at hepatic as 
well as at peripheral level.  Our study showed positive correlation (statistically 
significant) with fasting insulin, TG  which is in favor of  J Vrbikova et al (67) 
who demonstrated positive correlation of sICAM-1 with fasting and 
stimulated insulin and TG. Our study showed positive and statistically 
 significant correlation of sICAM-1 with TNF-α.  Our findings may suggest 
possible role of chronic low grade inflammation mediated by sICAM-1 and 
other inflammatory markers in defective pancreatic insulin secretion besides 
their established role in mediating peripheral insulin resistance. Our study also 
showed  that the treatment of PCOS subjects with OCP’s worsen the already 
elevated levels of sICAM-1  in these patients but no data is available till date 
studying the effect of OCP treatment on sICAM-1 level in women with PCOS. 
The elevated sICAM-1 levels in OCP group in our study indicate elevated 
inflammatory response. 
MCP-1 is an adipokine with insulin-resistance-inducing capacity that is 
related to increased adipose tissue mass in obesity and insulin resistance. It is 
thus a therapeutic target, and may represent an important factor linking 
adipose tissue inflammation, obesity and type 2 diabetes (258). In our study 
mild increase in MCP-1 levels in OCP treated PCOS women   was observed 
although it did not reached statistical significance. MCP-1 showed 
significant and positive correlation with blood glucose fasting and negative 
correlation with QUICKI. No significant correlation was found between MCP-
1 and other metabolic and insulin resistance markers in our study. Previous 
studies related to MCP-1 in PCOS by Glintborg D et al in 2009 showed that 
hirsute patients had significantly increased MCP-1 than controls of matched 
body composition. In PCOS, MCP-1 correlated positively with central fat 
mass (259). Recent data from Weihong Hu  et al, 2011 in both obese and non-
obese PCOS showed higher serum MCP-1 levels than controls and correlated 
positively with BMI, LH ,TG, Apo lipoprotein B and the ratio of Apo 
lipoprotein A/ Apo lipoprotein B (260). Serum CRP and MCP-1 levels were 
significantly higher in women with PCOS compared with controls (261). 
There is no data reported related to the effect of OCP’s on MCP-1 in women 
with PCOS.  Elevated MCP-1 levels in OCP group in our study indicated   
proinflammatory behavior of OCP’s. 
 TNF-α  an inflammatory cytokine (40) and is responsible for the expression of 
adhesion molecules such as VCAM-1 and ICAM-1 in the endothelium via 
NFκB (nuclear factor kappa B) pathway (41). In this study statistically 
insignificant increase in TNF-α levels in OCP treated PCOS women was 
found compared to the drug naive PCOS women. Previous studies showed 
increased levels of TNF-α in PCOS women as compared to controls. Ilhan 
Tarkun et al (2006)   also studied TNF-α and IL-6 levels in women with PCOS 
and demonstrated that TNF-α and IL-6 concentrations were elevated in normal 
weight women with PCOS (262). Interestingly, lean PCOS women had higher 
TNF-α levels than normal lean women while the levels were similar in obese 
PCOS and obese controls (Gonzelez et al) (42). Contrarily Sayin NC et al 
(2003) found similar TNF-α levels in patients with PCOS and with PCO; 
however, there was no correlation between the TNF-α and insulin, glucose and 
androgen levels in the study (263). Again we didn’t have a healthy control 
group to compare this part of observation.  Consequently our results may 
suggest that the treatment of PCOS subjects with OCP’s  may worsen the 
already elevated levels of TNF-α  indicating proinflammatory behavior and 
negative role of OCP’s.   
PAI-1 is mainly produced by the endothelium (cells lining blood vessels), but 
is also secreted by other tissue types, such as adipose tissue. PAI-1 inhibits the 
serine proteases tPA and uPA / urokinase, and hence is an inhibitor of 
fibrinolysis, the physiological process that degrades blood clots. In this study 
statistically insignificant increase in PAI levels in OCP treated PCOS women 
was found compared to the drug naive PCOS patients which suggests that 
OCP treatment elevates PAI levels in women with PCOS. In this study PAI 
showed statistically significant and positive correlation with blood glucose 
one hour, blood glucose two hour, insulin two hour and triglycerides. Previous 
studies related PAI levels in PCOS showed that plasma PAI-1 levels are 
elevated in overweight /obese women with PCOS but not in normal weight 
 women compared with BMI matched controls and that PAI-1 level are similar 
in the different phenotypes of the syndrome (264). In agreement with our 
findings higher PAI-1 levels in normal   weight women with PCOS were 
reported and a correlation between PAI-1 levels and both serum insulin levels 
and the HOMA-IR index was demonstrated (265-267). Our study suggests 
that OCP’s may have negative impact on the existing elevated procoagulant 
activity in PCOS women. However this effect seems mild in the present 
study.  No work has been done on the effect of OCP’s treatment on the PAI-1 
levels in PCOS till date. In contrast many smaller studies did not identify any 
difference in circulating PAI-1 levels between normal weight women with 
PCOS and BMI-matched healthy controls (268-270).  
In our study on comparison of factor VIII levels between the drug naive PCOS 
women and PCOS women treated with OCP’s, a significant decrease was 
found in OCP users. Factor 8 showed significant, negative correlation with 
fasting insulin, HOMA-IR and ICAM. No significant correlation was obtained 
between factor VIII and other metabolic parameters in our study. This result is 
conflicting as it does not fit the paradigm of other coagulation markers like 
PAI-1 and inflammatory markers. Previous studies have shown that OCP’s 
seem to have no effect on factor VIII levels (101,102). Robinson GE et al 
(1990) showed women taking the combined pill showed increases in 
fibrinogen and factor X and a reduction in anti thrombin III when compared 
with their control values. There were also small but significant increases in 
triglycerides and triglyceride-rich lipoproteins (188). Quehenberger P et al 
(1996) studied the effect of OCP treatment on selected factors involved in the 
activation i.e. circulating activated factor VII (cFVIIa), and in the inhibition of 
blood coagulation, i.e. plasma protein S activity and circulating 
thrombomodulin (cTM), these factors were measured for the first time in OCP 
users in a prospective study. They reported the increased level of activated 
factor VII and decreased plasma protein S activity and circulating 
 thrombomodulin during use of OCP’s (192). Van Rooijen M et al (2002) 
compared the effects of two different combined OCP on levels of plasma 
lipoproteins and coagulation factor VII. A significant rise in plasma 
triglyceride levels was obtained with both preparations, although the increase 
was more pronounced with ethinyl estradiol/desogestrel. Plasma 
concentrations of factor VII and activated factor VII were increased 
significantly only with ethinyl estradiol/desogestrel (195).Theoretically 
speaking and from the existing data factor VIII levels should be elevated with 
use of OCP’s as they are known to elevate procoagulant activity. At this 
moment we don’t seem to have an explanation for this finding which needs to 
be evaluated in future studies. 
In conclusion the present study was a pilot; it is the first attempt to investigate 
the role of OCP’s (E+P) on the worsening of metabolic abnormalities, insulin 
resistance, pro-inflammatory and procoagulant factors. Although OCP’s are 
commonly prescribed medications in women with PCOS and have significant 
benefit in clinical abnormalities, there is concern regarding their negative 
impact on the metabolic abnormalities. Our aim was address this concern. Our 
study findings imply that although OCP treatment helps in menstrual cyclicity 
and decreasing hyperandrogenism in women with PCOS, metabolic 
parameters such insulin resistance indices, glucose tolerance and lipid profile 
of PCOS subjects worsens with their use. In line with objectives of the present 
study we observed elevation of plasma concentrations of procoagulant (PAI-1) 
and proinflammatory (s-ICAM,MCP-1,TNF-α) markers in PCOS subjects 
treated with OCP’s. Interestingly our data did not suggest elevation of factor 
VIII levels which looks intriguing. We don’t have any apparent explanation 
for this contrary result at this moment and the finding needs to be looked at 
closely and in a systematic way to explain it.  Although, we did not have a 
control group to see the pre-existing procoagulant and proinflammatory 
activity in PCOS women, our data suggests that OCP group had unfavorable 
 profile as compared to full blown PCOS women who were not treated.  This 
indicates that E+P use in PCOS women can be viewed as unsafe and their 
routine use may be avoided. Larger controlled clinical trials with long term 
OCP use with graded doses with an arm of healthy control women on a larger 
cohort and more detailed   parameters of coagulation and inflammation with 
longitudinal follow up will likely answer the question. 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 6 
DISCUSSION   
 
Chapter 7 
CONCLUSION    
  
e studied 81 PCOS women diagnosed on the basis of Rotterdam 2003 
Criteria. Women who were not treated with any drug (controls, n=51) 
and PCOS women treated with OCP’s (cases, n=30) were recruited from 
various gynecological clinics. The women who consented and qualified the 
above criteria were subjected to detailed clinical, anthropometric, 
hemodynamic, hormonal and metabolic evaluation. In addition to OGTT 
derived insulin indices plasma levels of s-ICAM, MCP-1, TNF-α, PAI-1 and 
were measured using ELISA kits and factor VIII levels were measured using 
Coagulometric method. The results are briefly presented as follows: 
1) The mean age of controls and cases was (21.92±5.83 vs. 21.63±4.18 
years) respectively and was comparable (p=0.813).  
2) Similarly the mean age at menarche for controls and cases being 
(12.96±1.49 vs.13.13±1.27) years respectively and was comparable 
(p=0.597). 
3) Mean number of menstrual cycles per year for controls and cases was 
similar (9.12±3.88 vs.9.90±3.30) respectively which was comparable 
(p=0.358) but cycles were regular in OCP group. 
4) Mean   FG score of the controls and cases was (12.27±4.71vs. 
10.00±2.60) was statistically significant (p=0.017).  
5)  Mean weight of controls and cases was (58.57±8.52 vs.  59.07±6.34 
kg) indicating an insignificant weight gain in OCP group (p=0.782). 
Mean BMI (Body mass index) of controls and cases was (23.66±3.43 
vs. 24.07± 3.42 Kg/m²) respectively (p=0.606) which was marginally 
high in OCP group. Mean waist circumference of controls and cases 
was (79.96±10.15 vs. 78.20±8.49 cm) respectively (p=0.427). Mean 
W 
 waist hip ratio for controls and cases was (0.91±0.06 vs.  0.92±0.06) 
respectively which was comparable (p=0.544). 
6) Mean of systolic blood pressure in controls and cases was (122.24±6.99 
vs. 123.00±7.21 mm Hg) which was comparable (p=0.640). 
Mean diastolic blood pressure in controls and cases was (79.37±4.62 
vs. 79.46±4.29 mm Hg) which was comparable (p=0.928) which 
showed an insignificant trend towards elevation in OCP group.  
7) Mean   fasting   blood glucose in control and cases who participated in 
our study was (87.75±19.9 vs. 88.77±10.41 mg/dl) respectively which 
was comparable (p=0.795) which showed an insignificant trend 
towards elevation in OCP group.  
8)  Mean serum cholesterol level among controls and cases was (155.07 
±28.86 vs. 186.10±44.76 mg/dl) respectively which was statistically 
significant (p=0.000). Mean   serum   triglyceride levels   in controls 
and cases was (113.00±46.47   vs. 118.17±41.14 mg/dl) respectively 
which was comparable (p=0.616). Mean HDL cholesterol in controls 
and cases was (45.35±9.99 vs. 48.90±11.90 mg/dl) which was 
comparable (p=0.155). Mean LDL value in controls and cases was 
(83.20±27.6 vs. 118.45±45.66 mg/dl) respectively which was 
statistically significant (p=0.000). So OCP use is associated with 
elevation of Coronary risk as indicated by elevation of total and LDL 
cholesterol.  
9) Mean fasting insulin levels in controls and cases were slightly different 
(12.28±11.10 vs. 16.23±24.72 µIU/ml)) respectively which was 
comparable (p=0.326) indicating insulin resistance in the OCP group and 
thereby suggested a negative metabolic effect of OCP’s. Insulin two hour 
in controls and cases was found to be (43.43±36.07 vs. 
 65.69±63.67µIU/ml) respectively (p=0.48) showing insignificant 
elevation in OCP group.  FGIR (Fasting glucose to insulin ratio) in 
controls and cases was found to be (10.03±5.34 and 11.60±9.3) 
respectively which was comparable (p=0.336).  
10) HOMA-IR in controls and cases was found to be (2.73±2.64 vs. 
3.0±4.17) respectively which was comparable (p=0.335) indicating again 
impaired sensitivity. QUICKI (Quantitative Insulin Sensitivity Check 
Index) in controls and cases was found to be (0.516±0.01 vs. 
0.513±0.013) respectively which was comparable (p=0.449). FGIR 
(Fasting glucose to insulin ratio) in controls and cases was  (10.03±5.34 
& 11.60±9.3) respectively which was comparable (p=0.336) 
11) Mean LH value of controls and cases was found to be (8.17±6.14 vs. 
6.75±6.26 IU/L) respectively which is comparable (p=0.322). Mean 
FSH value in controls and cases was found to be (6.17±2.21 vs. 
4.88±2.17 IU/L) which is statistically significant (p=0.013) suggesting 
that OCP’s may decrease gonadotrphins.  
12) Mean   testosterone levels of controls and cases were found to be 
(63.31±31.30 vs.  56.05±31.81 ng/dl) (p=0.320) respectively which 
suggests antiandrogenic effect of OCP’s.  
13) Mean sICAM-1 values in controls and cases were found to be 
(312.41±131.65 vs. 417.03±131.65 ng/ml) respectively and was 
statistically significant (p=0.001). The elevated ICAM-1 levels in OCP 
group indicate elevated inflammatory response. 
14) Mean MCP-1value in controls and cases was found to be (456.78±187.2 
vs. 464.82 ± 91.19 pg/ml) (p=0.827) which shows worsening of 
inflammation in the OCP group. Similarly TNF-α levels in controls and 
cases were found to be (22.85±5.19 vs. 25.60±4.24 pg/ml) which is 
 statistically significant (p=0.016) again indicating proinflammatory 
behavior of OCP’s. 
15) PAI-1 is a key regulator of fibrinolysis and inhibits the activation of 
plasminogen to plasmin by both the tissue-type and the urokinase-type 
plasminogen activators. In addition, PAI-1 is a marker of insulin 
resistance (IR) and plasma PAI-1 antigen levels and activity are 
frequently elevated in insulin resistant states, including abdominal 
obesity, the metabolic syndrome and T2DM. Several prospective 
studies in the general population suggested that elevated PAI-1 levels 
are associated with increased risk for T2DM.Given the increased 
prevalence of insulin resistance in women with PCOS and the 
association between circulating PAI-1levels and IR, several studies 
assessed plasma PAI-1 levels in PCOS. Most, but not all, reported 
elevated plasma PAI-1 levels in women with PCOS. Mean PAI -1 levels 
in controls and cases were found to be (1.05±0.40 vs. 1.10±0.59 ng/ml) 
which is comparable (p=0.682).This suggests that OCP’s may have 
negative impact on the existing elevated procoagulant activity in PCOS 
women. However this effect seems mild in the present study.   
16) Mean plasma factor VIII levels in controls and cases was found to be 
(0.685±0.32 and 0.350±0.33) which is statistically significant (p=0.00). 
Theoretically speaking and from the existing data factor VIII levels 
should be elevated with use of OCP’s as they are known to elevate 
procoagulant activity. Interestingly the results from our study seem to 
be conflicting.   
In conclusion the present study was a pilot; it is the first attempt to investigate 
the role of OCP’S (Estrogen + Progesterone) on the worsening of metabolic 
abnormalities, insulin resistance, proinflammatory and procoagulant factors. 
Although OCP’s are commonly prescribed medications in women with PCOS 
and have significant benefit in clinical abnormalities, there is concern regarding 
 their negative impact on the metabolic abnormalities. Our aim was address this 
concern. Briefly short term use of OCP use in women with PCOS suggest 
worsening of already existing insulin resistance and glucose tolerance 
abnormalities although effect seems to be mild. Although, significant fall in 
serum testosterone translates into many clinical   benefits such as regularization 
of menstrual cycles, improvement in acne and other androgenic features, some 
unwanted abnormalities surfaced. OCP use was associated with elevated 
coronary artery disease risk factors such as total and LDL cholesterol levels. 
Similarly the elevated anti-fibrinolytic factor such as PAI-1 portends a high 
coronary risk. The procoagulant effect as estimated by serum factor VIII levels 
showed a fall in OCP users which cannot be explained. The proinflammatory 
markers (TNF-α and MCP-1) showed elevated levels after 3-6 month use of OCP 
suggesting worsening of inflammatory state. Larger controlled clinical trials with 
long term OCP use with graded doses need to understand the impact of OCP use 
on various biochemical, inflammatory and procoagulant state in the PCOS 
women.  
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